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ABSTRACT
Pathways, Networks and Therapy: A Boolean Approach to Systems Biology. (May 2012)
Ritwik Kumar Layek, B.Tech., Indian Institute of Technology, Kharagpur;
M.Tech., Indian Institute of Technology, Kharagpur
Co–Chairs of Advisory Committee: Dr.Aniruddha Datta
Dr. Edward R. Dougherty
The area of systems biology evolved in an attempt to introduce mathematical
systems theory principles in biology. Although we believe that all biological processes
are essentially chemical reactions, describing those using precise mathematical rules is not
easy, primarily due to the complexity and enormity of biological systems. Here we intro-
duce a formal approach for modeling biological dynamical relationships and diseases such
as cancer. The immediate motivation behind this research is the urgency to find a practica-
ble cure of cancer, the emperor of all maladies. Unlike other deadly endemic diseases such
as plague, dengue and AIDS, cancer is characteristically heterogenic and hence requires a
closer look into the genesis of the disease. The actual cause of cancer lies within our phys-
iology. The process of cell division holds the clue to unravel the mysteries surrounding
this disease. In normal scenario, all control mechanisms work in tandem and cell divides
only when the division is required, for instance, to heal a wound platelet derived growth
factor triggers cell division. The control mechanism is tightly regulated by several bio-
chemical interactions commonly known as signal transduction pathways. However, from
mathematical point of view, these pathways are marginal in nature and unable to cope with
the multi-variability of a heterogenic disease like cancer.
The present research is possibly one first attempt towards unraveling the mysteries
surrounding the dynamics of a proliferating cell. A novel yet simple methodology is de-
veloped to bring all the marginal knowledge of the signaling pathways together to form
iv
the simplest mathematical abstract known as the Boolean Network. The malfunctioning in
the cell by genetic mutations is formally modeled as stuck-at faults in the underlying Net-
work. Finally a mathematical methodology is discovered to optimally find out the possible
best combination drug therapy which can drive the cell from an undesirable condition of
proliferation to a desirable condition of quiescence or apoptosis. Although, the complete
biological validation was beyond the scope of the current research, the process of in-vitro
validation has been already initiated by our collaborators. Once validated, this research
will lead to a bright future in the field on personalized cancer therapy.
vTo my family
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1CHAPTER I
INTRODUCTION
Biology is a natural science concerning the study of life and living organisms. The tradi-
tional approach to biology advocates that life is also a complex manifestation of physical
interactions. However, even in the 21st century, science has not been able to decipher the
complete picture of this bottom-up approach towards biology. Indeed, it is fair to say that
we have a long way to go to establish biology on a firm mathematical basis.
As scientific researchers, our main goal is to ferret out the inherent truth from differ-
ent natural phenomena to the best of our ability, and for this we employ standard scientific
techniques such as mathematical modeling, design of experiments, actual experimentation,
data collection, data interpretation and validation. In the last few centuries, mathematics
has grown enormously to accommodate the modeling and experimental paradigms for the
elucidation of scientific theories.
However, unlike the physical sciences, biology continues to predominantly be an ob-
servational science. For instance, if we examine the work of early stalwarts like Charles
Darwin or Gregor Johann Mendel, we see that their postulates and theories are mostly ob-
servational and intuitive in nature. Although several centuries have elapsed since then and
technology has evolved a lot, philosophically we are still treating biology as an observa-
tional science. In addition to technical challenges, biological research through the ages has
been impeded by human ethical and morality considerations. For instance, the anatomical
dissection of dead bodies was prohibited during the medieval period, and even today em-
bryonic stem cell research is restricted throughout the world although it has the potential to
yield easier solutions for treating diseases requiring organ transplantation.
The journal model is IEEE Transactions on Automatic Control.
2Before going into the actual introduction to the current dissertation, it behooves us to
take a look at the timeline of the major developments in the biological sciences (Table I and
II).
Although the discoveries listed in Tables I and II are by no means comprehensive, they
do provide us with some flavor of the mainstream biological research. We note that there
is no theorem or formula or mathematical model associated with most of these discover-
ies. The recent advancements in genetics, genomics and medical science have introduced
a critical need for mathematically rigorous approaches in biological research. However,
unfortunately, we still have a long way to go.
A. Systems biology
For a moment, let us think about the status of physics prior to Galileo Galilei(1564 AD-
1642 AD) and Isaac Newton (1642 AD-1727 AD). At that time, physics was not a coherent
science. Medieval physicists were busy doing research on the perpetual motion machine,
the elixir of life and the sorcerer’s stone, to name a few. Without proper mathematical back-
ground and systematic understanding most research during that time was in some sense an
exercise in futility. A similar observation could be made about the biological research
during the last century. Without proper mathematical modeling of the inherent dynamical
system, research on fundamental biology and medicine mostly focussed on the good old
methods of trial and error. However, even during this time, several scientists such as Erwin
Schrodinger and Norbert Wiener understood that the unification of mathematics and biol-
ogy could prove to be extremely beneficial. The new direction that emerged from this idea
of unification is called ‘Systems Biology’.
There are numerous definitions of systems biology but we want to mention the one
given by The National Institute of Health (NIH).
A discipline at the intersection of biology, mathematics, engineering and the physical sci-
3Table I. Major Breakthroughs in Biology before 1800 AD [1].
Year Breakthrough
520 BC Alcmaeon of Croton distinguished veins from arteries and
discovered the optic nerve.
450 BC Sushruta wrote the Sushruta Samhita, describing over 120
surgical instruments and 300 surgical procedures, classify-
ing human surgery into eight categories, and introducing
cosmetic and plastic surgery.
450 BC Xenophanes examined fossils and speculated on the evolu-
tion of life.
350 BC Aristotle attempted a comprehensive classification of ani-
mals.
300 BC Herophilos dissected the human body.
150 AD Claudius Galen wrote numerous treatises on human
anatomy.
800 AD Al-Jahiz describes the struggle for existence, introduces the
idea of a food chain, and adheres to environmental deter-
minism.
1628 AD William Harvey published ’An Anatomical Exercise on the
Motion of the Heart and Blood in Animals’.
1658 AD Jan Swammerdam observed red blood cells under a micro-
scope.
1663 AD Robert Hooke saw cells in cork using a microscope.
1683 AD Anton van Leeuwenhoek observed bacteria.
4Table II. Major Breakthroughs in Biology after 1800 AD [1].
Year Breakthrough
1828 AD Friedrich Woehler synthesized urea; first synthesis of an or-
ganic compound from inorganic starting materials.
1856 AD Louis Pasteur stated that microorganisms produce fermen-
tation.
1858 AD Charles R. Darwin proposed a theory of biological evolu-
tion.
1865 AD Gregor Mendel demonstrated in pea plants that inheritance
follows definite rules.
1869 AD Friedrich Miescher discovered nucleic acids in the nuclei of
cells.
1902 AD Walter Sutton and Theodor Boveri, independently proposed
that the chromosomes carry the hereditary information.
1928 AD Alexander Fleming discovered the first antibiotic, peni-
cillin.
1953 AD James D. Watson and Francis Crick published a double-
helix structure for DNA.
1961 AD J. Heinrich Matthaei cracked the first codon of the genetic
code.
1996 AD Dolly the sheep was first clone of an adult mammal.
2001 AD Publication of the first draft of the complete human genome.
5ences that integrates experimental and computational approaches to study and understand
biological processes in cells, tissues and organisms. Studies at the systems level are distin-
guished not only by their quantitative nature in data collection and mathematical modeling,
but also by their focus on interactions among individual elements such as genes, proteins
and metabolites. These studies often integrate data from multiple levels of the biological
information hierarchy in an environmental and evolutionary context and pay particular
attention to dynamic processes that vary in time and space. Successive iterations of ex-
periment and theory development are characteristic of systems biology. When applied to
human health, systems biology models are intended to predict physiological behavior in re-
sponse to natural and artificial perturbations and thereby contribute to the understanding
and treatment of human diseases[6].
The current dissertation will provide a preliminary but novel approach for mathemat-
ical modeling of different cellular phenomena and its possible application in systems biol-
ogy. To put the subsequent chapters in proper context, in the next few sections we will dis-
cuss several biological processes which require mathematical insight and modeling. This
discussion on cell biology, genetics and genomics is necessary to properly appreciate the
motivation and flow of this dissertation.
1. Biology of the cell
The word ‘cell’ comes from the the Latin word ‘cellula’ meaning a small room. Cells are
membrane bounded units containing different organelles performing different functions. A
cell is the basic unit of life. The simplest forms of life may be solitary cells that reproduce
by dividing in two, while higher organisms are ensemble of cells where a group of cells is
designated for a particular functionality.
Living cells emerged on earth about 3.5 billion years ago, possibly by spontaneous
reactions between molecules in an environment that was far from chemical equilibrium.
6These reactions formed some simple organic molecules like amino acids, sugars, etc which,
by polymerization through peptide bonds and phosphodiester bonds, then led to the forma-
tion of polypeptides and polynucleotides (RNA), that could catalyze their own replications.
With time, one of these families of cooperating RNA catalysts developed the ability for di-
rect synthesis of polypeptides. Finally, as the accumulation of additional protein catalysts
allowed more efficient and complex cells to evolve, the DNA double helix replaced RNA
as a more stable molecule for storing the increased amount of genetic information required
by such cells[2].
A schematic diagram of a typical eukaryotic cell is shown in Fig. 1.
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Fig. 1. An Eukaryotic Cell.
7From this diagram we can see the important components of the eukaryotic cell. Brief
descriptions are given below[2, 1].
• Cell membrane: The cell membrane is a selectively permeable membrane made up
of a lipid bilayer and embedded proteins. It protects the intra-cellular environment
and helps the cell in its motility and communication.
• Nucleus: The nucleus is a central part of the cell containing most of the cell’s genetic
material, organized as multiple DNA molecules in combination with a large variety
of proteins to form chromosomes. Its function is to maintain the integrity of the DNA
and to control the activities of the cell by regulating gene expression.
• Nucleolus: Nucleolus is a discrete densely stained structure inside the nucleus. Its
main role is to transcribe ribosomal RNA (rRNA) and assemble ribosomes.
• Endoplasmic Reticulum(ER): Endoplasmic reticulum is an interconnected network
of tubules and vesicles. Rough endoplasmic reticulum (with ribosomes) synthesizes
and transports proteins, while smooth endoplasmic reticulum (without ribosome)
synthesizes lipids, steroids and morphine, metabolizes carbohydrates, regulates drug
metabolism and the attachment of receptors on cell membrane proteins.
• Ribosome: Ribosome is the protein factory in the cell. The mRNA (messenger RNA)
molecule leaves the nucleus and enters the Ribosome. Ribosome reads the codons
(nucleotide triplets) from the mRNA and puts the corresponding amino acids accord-
ing to the genetic code.
• Mitochondrion: Mitochondrion is the power plant of the cell. This membrane en-
closed organelle supplies the Adenosine triphosphate (ATP) required by the cell for
meeting its energy needs.
8• Lysosome: Lysosome destroys cellular debris by using its hydrolase enzymes. It
helps the cell to rejuvenate by destroying old organelles. It is also known as the
‘suicide bag’ of the cell.
• Golgi apparatus: Golgi apparatus processes and packages protein molecules for de-
livering elsewhere. It helps in intra-cellular communication and secretion.
• Vacuoles: Vacuoles are membrane bound organelles used for carrying toxic elements
out of the cell, maintaining pressure and pH inside the cell.
2. DNA, gene, genetic code and the central dogma of molecular biology
Deoxyribonucleic acid (DNA) contains most of the genetic instructions inside the cell.
The DNA segments carrying these instructions are called genes. DNA consists of two
long strands of nucleotides with backbones made of sugar and phosphate joined by phos-
phoester bonds. These two strands run in opposite directions to each other. Attached to
each sugar is one of the four types of bases - Adenine(A), Guanine(G), Cytosine(C) and
Thymine(T). Adenine and Guanine belong to the double ringed class of molecules called
purines, whereas cytosine and thymine are single ringed pyrimidines. It is the sequence
of these four bases along the backbone that encodes the genetic information. In the dou-
ble helical DNA structure, Adenine always binds with Thymine and Cytosine binds with
Guanine through triple and double bonds respectively. Ribonucleic acid (RNA) is the tem-
porary carrier of genetic instructions from the DNA to the Ribosome. RNA is a single
stranded polynucleotide containing Uracil(U) in liu of Thymine(T).
Amino acids serve as the building blocks of protein. There are twenty amino acids
which are naturally incorporated into polypeptides.
The genetic code provides the unique map between the sequence of three consecutive
bases(codon) in the mRNA and the amino acids (Table III) [7]. The mRNA molecule is
decoded on ribosomes using the genetic code to synthesize the relevant protein. The steps
9Table III. The Genetic Code [2].
Amino acid/control code(s)
Alanine/Ala/A GCU, GCC, GCA, GCG
Arginine/Arg/R CGU, CGC, CGA, CGG, AGA, AGG
Asparagine/Asn/N AAU, AAC
Aspartic acid/Asp/D GAU, GAC
Cysteine/Cys/C UGU, UGC
Glutamine/Gln/Q CAA, CAG
Glutamic acid/Glu/E GAA, GAG
Glycine/Gly/G GGU, GGC, GGA, GGG
Histidine/His/H CAU, CAC
Isoleucine/Ile/I AUU, AUC, AUA
Leucine/Leu/L UUA, UUG, CUU, CUC, CUA, CUG
Lysine/Lys/K AAA, AAG
Methionine/Met/M AUG
Phenylalanine/Phe/F UUU, UUC
Proline/Pro/P CCU, CCC, CCA, CCG
Serine/Ser/S UCU, UCC, UCA, UCG, AGU, AGC
Threonine/Thr/T ACU, ACC, ACA, ACG
Tryptophan/Trp/W UGG
Tyrosine/Tyr/Y UAU, UAC
Valine/Val/V GUU, GUC, GUA, GUG
Start AUG
Stop UAA, UGA, UAG
10
for going from DNA to protein are as follows.
DNA sequences are copied into RNA molecules in the process termed Transcription; a
gene that is transcribed is said to be actively expressed, while a gene that is not transcribed
is considered as repressed. Normally transcription of a gene yields an RNA molecule
of length similar to the gene itself. Once synthesized, the base sequences of the RNA
molecule are translated by the ribosomes into a sequence of amino acids. The resulting
molecule folds up into a unique three-dimensional configuration and becomes a functional
protein [8]. The complete unidirectional information flow for protein biosynthesis from the
gene is referred to as the central dogma of molecular biology (Fig. 2).
D N A
R N A
P r o t e i n
T r a n s c r i p t i o n
T r a n s l a t i o n
N u c l e u s
Fig. 2. Central Dogma of Molecular Biology.
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3. Genetic regulation
Some proteins in the cell are called housekeeping proteins. Their corresponding genes are
constitutively active to maintain the protein concentration. However, there are certain other
proteins which are normally not present inside the cell all the time. Only when the protein
is required, the corresponding gene is turned ‘ON’. The mechanism by which a particular
gene is turned ‘ON’ or ‘OFF’ is called genetic regulation. The proteins which can bind to
the DNA to start the transcription process are called transcription factors. These transcrip-
tion factors are also regulated by other transcriptional or enzymatic activities. The complex
gene-protein-RNA interactions are instrumental in maintaining cellular homeostasis.
From a systems viewpoint, the behavior of a living cell is analogous to that of a multi-
input-multi-output (MIMO) feedback system. Understanding this system is the most im-
portant challenge in systems biology.
4. Signal transduction pathways
In multi-cellular organisms, life is sustained by a systematic coordination between differ-
ent cells and all extra cellular signals. Each cell has its own functionality and its future
is determined by various intrinsic and extrinsic biological signals. For instance, a cell’s
proliferation, differentiation or induction of apoptosis are determined by a number of dif-
ferent signals. From the time of a cell’s birth (by division of its parent cell), the cell’s state
is tightly controlled by different biological regulations. Cell signaling is a form of com-
munication between different cells. These signals can be chemical or electrical impulses.
Communication via electrical impulses is typically associated with nerve cells (neurons)
which are attached to each other and the action potential transmits from neuron to neuron.
For general somatic cells, proteins are usually the signaling molecules used for communi-
cation. The interactions between the different signaling molecules are multivariate in nature
and hence difficult to study. As a result, historically biologists have focussed on studying
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the marginal interaction between the signaling molecules, leading to what is called path-
way information. Although pathway knowledge cannot provide the complete multivariate
picture of the overall cellular signal transduction, it is clear that one has to have a mech-
anism for incorporating this prior information into any signal transduction model that one
develops. An approach to do precisely that will be discussed elaborately in CHAPTER III
and is also reported in [9].
5. Systems medicine
The area of systems medicine focusses on the problem of treating a complex disease such
as cancer. Any disease is nothing but the lack of order in the system. Systems diseases such
as cancer are possibly caused by mutations in the DNA. Malfunctions in the interactions
between the genes and proteins cause disruption in the normal cellular dynamics. Systems
medicine seeks to restore the earlier dynamics of the cell or terminate the cell if such
restoration is not possible. This problem is different from that in systems biology because
here controlling the dynamics of the system is more important than knowing the system
accurately. In systems theory, there are different approaches for controlling a system even
if the system is not fully known. CHAPTERs II and IV discuss therapeutic intervention
and systems medicine and these results have been also reported in [10] and [11].
B. Dynamical systems
Before starting the mathematical modeling of biological systems, it is appropriate to intro-
duce dynamical systems. A dynamical system can be thought of as a rule for determining
the time evolution of a system state (vector). Although any real world dynamical system
is continuous both in time and space, for modeling simplicity we often discretize these
variables. In addition, the mathematical rule determining the state transition can be either
deterministic or stochastic. Based on these considerations, we can get different kinds of
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dynamical systems as shown in Fig. 3.
Fig. 3. Dynamical Systems.
Although the actual protein concentrations in the cell are continuous variables, there
are at least three reasons why a discrete type of modeling would be preferred. First, al-
though the continuous model may dictate the exact dynamics, using the current technology
it is impossible to reliably measure the concentration of each protein inside the cell in real
time. Second, many of the genes/proteins inside the cell exhibit ON/OFF switch-like be-
havior which is more readily accommodated using quantization within the digital domain
[12], [13]. Third, the discrete-time systems are easier to analyze, model and control in
real time in comparison to continuous-time systems [14]. Hence, in this dissertation we
talk mostly about the two discrete-time discrete-state models namely, Boolean Network
(BN) and Markov Chain/Probabilistic Boolean Network (PBN). BN and PBN are formally
introduced in CHAPTERs II and III.
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C. Dissertation outline
The dissertation is organized as follows:
• CHAPTER II: Boolean networks and probabilistic Boolean networks are formally
introduced as two simple models of genetic regulatory networks. Adaptive inter-
vention in generic probabilistic Boolean networks(BN is a trivial subset of PBN)
is described as a method for arriving at an intervention strategy that is practically
implementable.
• CHAPTER III: Cell signaling pathways are considered to be the knowledge base
for building Boolean networks. The synthesis algorithm is explained in detail and
illustrative examples are included. Some experimental validation results from the
existing literature are also presented.
• CHAPTER IV: Intervention strategies are designed for both combinatorial and se-
quential Boolean networks based on some realistic modeling of therapeutic inter-
vention. An example of the growth factor mediated pathways is presented, and this
example is relevant to cell cycle control and cancer. An intervention strategy is also
designed for a sequential Boolean network (or a feedback network). An example
from DNA damage stress response pathways is presented.
• CHAPTER V: Finally a futuristic research direction for systems biology is outlined
where the starting point for experimental design is the existing knowledge from past
biological research.
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CHAPTER II
GENETIC REGULATORY NETWORKS: MODELING AND INTERVENTION*
There are two major objectives for modeling of genetic regulatory networks: (i) to
better understand inter-gene (and protein) interactions and relationships on a holistic level,
thereby facilitating the diagnosis of disease; and (ii) to design and analyze therapeutic inter-
vention strategies for shifting the state of a diseased network from an undesirable location
to a desirable one. Many different approaches have been proposed in the literature for
modeling the behaviour of genetic regulatory networks. Of these, the model which has
received the most attention in the context of therapeutic intervention is the probabilistic
Boolean network (PBN). To date, a number of approaches have been proposed for carrying
out interventions in PBNs based on stochastic optimal control theory for Markov chains
[15, 16, 17]. These assume perfect knowledge of the underlying PBN, an assumption
which, when not satisfied in practice, can lead to degraded or unacceptable performance.
To remedy the situation, one could design a fixed intervention strategy that is “robust”, or
somewhat insensitive, to modeling errors, in particular, to the effect of uncertainties in the
transition probability matrix of a PBN, Another approach is to “tune” the intervention strat-
egy to the actual network via on-line adaptation. The aim of this chapter is to demonstrate
the feasibility of such an adaptive approach in the framework of PBNs. At the very outset,
it is important to point out that such a scheme is feasible only if the uncertainty belongs to
a specific class and prior knowledge about this class can be incorporated into the design.
*Part of this chapter is reprinted with permission from “Adaptive intervention in prob-
abilistic boolean networks” by R. Layek, A. Datta, R. Pal, and E. R. Dougherty, 2009,
Bioinformatics, vol. 25, no. 16, pp. 2042-2048, Copyright [2009], Oxford University
Press. (http://bioinformatics.oxfordjournals.org/content/25/16/2042.short)
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A. Systems and methods
1. Probabilistic Boolean networks
A Boolean Network (BN), Υ = (V, F ), on n genes is defined by a set of nodes/genes
V = {x1, ..., xn}, xi ∈ {0, 1}, i = 1, ..., n, and a list F = (f1, ..., fn), of Boolean functions,
fi : {0, 1}
n → {0, 1}, i = 1, ..., n [18]. Each node xi represents the state/expression of
the ith gene, where xi = 0 means that gene i is OFF and xi = 1 means that gene i
is ON. The function fi is called the predictor function for gene i. Updating the states
of all genes in B is done synchronously at every time step according to their predictor
functions. At time t, the network state is given by x(t) = (x1(t), x2(t), ..., xn(t)), called a
gene activity profile (GAP). The state (GAP) transition diagram of a typical BN is shown
in Fig. 4(a). A Probabilistic Boolean Network (PBN) consists of a set of nodes/genes
V = {x1, ..., xn}, xi ∈ {0, 1, ..., d}, i = 1, ..., n, and a set of vector valued network
functions, f1, f2, ..., fk, governing the state transitions of the genes. For j = 1, 2, ..., k,
fj = (fj1, fj2, ..., fjn), where fji : {0, 1, ..., d}n → {0, 1, ..., d}, i = 1, ..., n [19, 20]
In most applications, the discretization is either binary or ternary. Here we use binary
quantization, d = 1, which presents no theoretical limitation on the development. At
each time point a random decision is made as to whether to switch the network function
for the next transition, with the probability q of a switch being a system parameter. If
the decision is to switch, then a new function is chosen from among f1, f2, ..., fk, with cj
being the probability of choosing fj (network selection is not conditioned by the current
network, which can itself be selected). Each network function fj determines a BN, the
individual BNs being called the contexts of the PBN. The PBN behaves as a fixed BN until
a decision is made to switch contexts according to the probabilities c1, c2, ..., ck from among
f1, f2, ..., fk. If q = 1, the PBN is said to be instantaneously random; if q < 1 [21], the PBN
is said to be context-sensitive. We consider PBNs with perturbation, meaning that at each
time point there is a probability p of any gene flipping its value uniformly randomly. Since
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there are n genes, the probability of a random perturbation at any time point is 1− (1−p)n.
A context-sensitive PBN determines a Markov chain whose states are (context, GAP) pairs.
The transition probability from (s,y) to (r,x) is given by
Ps,y(r,x) = 1[r=s]((1− q) + qcs){1[fs(y)=x](1− p)
n
+ 1[x 6=y]p
η(x,y)(1− p)n−η(x,y)} (2.1)
+ 1[r 6=s]qcr{1[fr(y)=x](1− p)
n
+ 1[x 6=y]p
η(x,y)(1− p)n−η(x,y)},
The state (GAP) transition diagram of a typical PBN (or Markov Chain) is shown in Fig.
4(b). where r, s denote the rth and sth BNp (Boolean Network with perturbation), which
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Fig. 4. State Transition Diagrams for a Boolean Network and a Probabilistic Boolean Net-
work.
are the BNps at time t+ 1 and t, where η(x,y) is the Hamming distance between x and y,
and 1[f(y)=x] is the indicator function that takes value 1 if f(y) = x according to the rule
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structure and is equal to 0 otherwise. The random perturbation makes the Markov chain
irreducible and ergodic. Thus, it possesses a steady-state distribution. Since there are k
contexts and 2n GAPs in each network, the Markov chain possesses k2n states and we can
relabel the states with z(t) ∈ {0, 1, 2, · · · , 2nk − 1} being the state that is occupied by the
network at time t. For an instanteously random PBN, the Markov chain reduces so that its
states are the GAPs of the PBN. The transition probability expression (2.2) can be used to
track the time evolution of the (context, GAP) state. In practice it may be impossible to
detect context, only the GAP. We obtain the transition probabilities between the GAPs by
taking the expectation of the (context, GAP) transition probabilities over the networks, the
transition probability from GAP y to GAP x being given by
Py(x) = (1− p)
n
k∑
i=1
1[fi(y)=x]ci + 1[x 6=y]p
η(x,y)(1− p)n−η(x,y) (2.2)
Using the above equations we can compute the 2n× 2n transition probability matrix corre-
sponding to the averaged context-sensitive PBN. As shown in [22], the transition probabil-
ity matrix for an averaged context-sensitive PBN is the same as that of an instantaneously
random PBN that makes use of the same constituent Boolean networks. It is possible that
some of the transition probabilities computed using (2.2) may evaluate out to zero. The cor-
responding transitions are referred to as forbidden transitions and the adaptive algorithms
to be presented in this chapter require that the set F of such forbidden transitions be known.
Remark 1. The transition probability expressions derived in this subsection allow for the
possibility of different selection probabilities for the different constituent Boolean networks
of a PBN. However, in the absence of any prior knowledge, we will henceforth assume a
uniform distribution of the selection probabilities, i.e. ci = 1k , i = 1, 2, · · · , k.
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2. Infinite-horizon control: perfect modeling
In this section, we summarize some results on the infinite-horizon control of PBNs, assum-
ing perfect modeling. A PBN with control can be modeled as a stationary discrete-time
dynamic system
zt+1 = f(zt, ut, wt), t = 0, 1, ...., (2.3)
where for all t, the state zt is an element of a state space S , the control input ut is an element
of a control space C, the disturbancewt is an element of a spaceD and f : S×C×D 7→ S.
1 In the particular case of a PBN with n genes composed of m Boolean networks with
perturbation probability p and network transition probability q, S = {0, 1, 2, ......, m(2n −
1)} and the control input ut is constrained to take values in the spaceC = [0, 1, ....., 2k−1],
where k is the number of binary control inputs. The disturbance wt is manifested in terms
of change of network based on the network transition probability q or change of state due
to perturbation probability p. wt is independent of prior disturbances w0, w1....wt−1. The
objective is to derive a sequence of control inputs, a control strategy, such that some cost
function is minimized over the entire class of allowable control strategies. We define a cost
per stage, g˜(i, u, j), depending on the origin state i, the destination state j, and the applied
control input u. 2 The actual design of a “good” cost function is application dependent and
is likely to require considerable expert knowledge. In finite-horizon control one can sum
the costs over the number of time points constituting the horizon and take the expectation;
however, this cannot safely be done with infinite horizon because the summation of the
1In the rest of this chapter, we will be denoting the time dependence of z, u and w by
the subscript t. In all other situations, the context will make it clear whether a subscript
denotes time dependence or reference to the particular component of a vector.
2Note that while finite horizon control problems in the literature allow for costs-per-
stage functions that vary from one stage to another, infinite horizon control problems in
the literature have typically been derived assuming that the same cost per stage function
is used for all stages. For PBNs (both context sensitive and otherwise), this is not of any
consequence since all of our earlier finite horizon results also used the same cost per stage
function for all stages.
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one-stage costs might diverge to infinity (for all controls), thereby leading to an ill-posed
optimization problem. One way to avoid the problem of a possibly infinite total cost is by
considering the average cost per stage which is defined by
Jpi(z0) = lim
M→∞
1
M
E{
M−1∑
t=0
g˜(zt, µt(zt), zt+1)} (2.4)
where the expectation is with respect to both origin and destination states. In this formu-
lation, a control policy pi = {µ0, µ1, · · · } is chosen to minimize the above cost and the
problem is referred to as the average cost per stage problem. Minimization of the total cost
is feasible if Jpi(z0) is finite for at least some admissible policies pi and some admissible
states z0. If there is no zero-cost absorbing state (which is the case in context-sensitive
PBNs with perturbation), then the total cost will frequently go to ∞. Hence the average
cost per stage formulation is essential when we are interested in the condition of the pa-
tient in the long run and equal importance is given to the patient’s condition in all stages. In
general, the cost g˜(i, u, j) of moving from state i to state j under control u may depend on
the starting state i; however, in the case of PBNs, we have no obvious basis for assigning
different costs based on different initial states. Accordingly, we assume that the penalty
g˜(i, u, j) is independent of the starting state i and its value is based on the control effort
and the terminal state j. The penalty is high if the end state is a bad state regardless of the
starting state, and vice-versa. Hence g˜(i, u, j) = g˜(u, j). Moreover, since in Eq. 2.4 the
cost is obtained by taking the expectation with respect to the origin and destination states,
it is possible to replace g˜(zt, ut, zt+1) by an equivalent cost per stage that does not depend
on the destination state by taking the expectation with respect to the destination state and
leaving only the expectation with respect to the original state. More specifically, we use as
cost per stage the expected cost g(i, u) given by [23]:
g(i, u) =
2n−1∑
j=0
pij(u)g˜(i, u, j) =
2n−1∑
j=0
pij(u)g˜(u, j) (2.5)
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where pij(u) is the transition probability under control u.
To solve the average-cost-per-stage optimal control problem, let Π denote the set of
all admissible policies pi, i.e., the set of all function sequences pi = µ0, µ1, .... with µt(x) :
S → C, t = 0, 1, ...... The optimal cost function J∗,which is independent of the initial state
[23], is defined by
J∗ = min
pi∈Π
Jpi(z), z ∈ S is arbitrary. (2.6)
A stationary policy is an admissible policy of the form pi = µ, µ, .... Its corresponding cost
function is denoted by Jµ. A stationary policy pi = µ, µ.... is optimal if Jµ(z) = J∗(z) for
all states z.
To minimize the cost function of Eq. 2.4, first defiine the mapping
Jt(i) = min
u∈C
[
g(i, u) +
2n−1∑
j=0
pij(u)Jt+1(j)
]
(2.7)
which, although we will not go into detail, provides the dynamic programming solution for
the finite-horizon problem [23]. Secondly, for any cost function J : S → ℜ, define the
mapping TJ : S → ℜ by
(TJ)(i) = min
u∈C
[g(i, u) +
2n−1∑
j=0
pij(u)J(j)], i ∈ S. (2.8)
We note in passing that TJ is the optimal cost function for the one-stage (finite horizon)
problem that has stage cost g and terminal cost J . For the average-cost-per-stage problem,
the value iteration Jt+1(i) = TJt(i) cannot be used directly because it may diverge to
infinity. Thus, calculating the average cost by taking limM→∞(JM/M) is not feasible.
Instead, we consider a differential cost ht obtained by subtracting a fixed component of Jt,
say Jt(n1), from each element of Jt, i.e.,
ht(i) = Jt(i)− Jt(n1), ∀i ∈ S. (2.9)
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Letting e = [1, 1, 1, · · · , 1]T , the above relationship can be rewritten in vector form as
ht = Jt − Jt(n1)e.
Some algebraic manipulations [17] yield
ht+1 = Tht − (Tht)(n1)e
as the value iteration algorithm for the differential cost. Using some additional arguments,
we can arrive at the following policy iteration algorithm for the average cost case [23, 17]:
• 1. (Initialization): An initial policy µ0 is selected.
• 2. (Policy Evaluation): Given a stationary policy µk, we obtain the corresponding
average and differential costs λk and hk(i) satisfying
λk + hk(i) = g (i, µk(i)) +
2n−1∑
j=0
pij(µk(i))hk(j), i ∈ S (2.10)
This linear system of equations can be solved utilizing the fact that hk(n1) = 0,
where n1 ∈ S is any particular reference state.
• 3.(Policy improvement): An improved stationary policy µk+1 satisfying
g
(
i, µk+1(i)
)
+
2n−1∑
j=0
pij(µk+1(i))hk(j)
= min
u∈C
[
g (i, u) +
2n−1∑
j=0
pij(u)hk(j)
]
. (2.11)
is obtained. The iterations are stopped if µk+1 = µk, else we return to Step 2 and
repeat the process.
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3. Adaptive infinite-horizon control
We now consider an adaptive intervention strategy that can be used in the presence of model
uncertainty. We assume that the underlying network is modeled by a member of a known
finite family of PBNs and we have no a priori knowledge about which member of that
family models the actual network. In such a situation, a natural approach is to estimate the
model number on-line and then use policy iteration to determine the corresponding con-
troller. This is the principle of adaptive control and considerable theoretical research has
been aimed at showing that such certainty equivalence schemes can provide the required
performance [24, 25]. Our focus will be to demonstrate via simulations the feasibility of
adaptive intervention in the context of gene regulatory networks. We will use a variation of
an adaptive control algorithm developed in [26] for unknown Markov chains, to which we
refer for technical proofs of convergence. While the scheme in [26] attempts to estimate
all entries of the transition probability matrix, our adaptive algorithm will estimate only the
model number since our underlying assumption is that the transition probabilities of the
PBN are completely determined, once we know the model number.
There are a number of ways in which one can possess a list of PBNs and thereby be
presented with the problem of adaptively determining a model number. Several inference
procedures produce PBNs by way of first producing Boolean networks satisfying some
desired relation to the data. In [27], Boolean networks are constructed whose attractor
structures coincide with data points assumed to be in attractors in the true biological net-
work, along with the networks satisfying certain constraints, such as the number of predic-
tors. Then one or more PBNs are constructed from these Boolean networks by comparing
the steady-state distributions of potentially inferred PBNs with the full set of experimental
data. In [28], Boolean networks are inferred by first using a Bayesian approach to generate
regulatory graphs (topologies) most compatible with the data and then inferring the predic-
tors via a nonlinear perceptron model, using a reversible jump Markov chain Monte Carlo
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(MCMC) method. Then one or more PBNs are constructed from the Boolean networks
by using Bayesian scores. In [29], a single PBN is constructed such that each constituent
Boolean network is consistent with the data, the estimate of the expected distribution of
the data generated by the PBN using its steady-steady state distribution agrees with the
distribution of the data, and the latter condition cannot be accomplished with less than the
number of constituent networks in the inferred PBN. While this leads to a single PBN,
in order that the inferred PBN not overfit the data, and in the process be composed of an
inordinately large number of Boolean networks, the data are first filtered. Thus, different
filtering techniques can lead to different PBNs.
In each of the preceding cases, rather than settle on a single PBN model when apply-
ing control, one can take the view that there is a list of potential PBNs and that new data are
to be used to adaptively determine the control policy. Moreover, in the cases of [27] and
[28],one might not even form a PBN and simply treat the problem in the framework of a
collection of Boolean networks, in which the adaptation is aimed at selecting a control pol-
icy for the governing Boolean network, a view compatible with our proposed algorithms.
This latter view, that one has a collection of Boolean networks, absent a PBN structure,
was taken in [30], where a finite-horizon control policy was determined that performed op-
timally relative to the family of networks. Here we would proceed adaptively.
In addition to inference, there is another way in which a list of PBNs can naturally
occur. In [31] and [32], a PBN is derived from a mammalian cell cycle network proposed
in [33] by assuming a mutation that leads to a cancerous phenotype. Specifically, in the
mutation, the gene p27 can never be activated, the result being that the cell can cycle in
the absence of any growth factor. A different mutation will lead to a different PBN. Thus,
based on a given network, in this case the one proposed in [33], if one is unsure of the mu-
tation that has led to a cancerous phenotype, then new data utilized in an adaptive fashion
can be used to design an intervention strategy.
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Suppose the family of controlled PBNs is parametrized by the parameter α ∈ Awhere,
for any α ∈ A,
∑
j∈S p(i, j, u, α) = 1 for any (i, u) ∈ S×C. 3 The only constraint on A is
that every element of A results in a set of bonafide transition probabilities. The cardinality,
|A|, of A determines the total number of possible PBNs. For each α ∈ A, we can compute
the uncontrolled transition probability matrix by using (2.2). In addition, for a given control
gene, the rows of the controlled transition probability matrix can be determined as a linear
transformation of the rows of the uncontrolled transition probability matrix. As shown in
[34], this is a consequence of restricting the class of allowable interventions to the flipping
of a chosen control gene. We use the adaptive control algorithm originally derived in [26]
by maximizing a modified likelihood criterion. For each α ∈ A, let J∗(α) be the optimal
long term average cost obtained for model α using the method of the last sub-section and let
φ(., α) : S → C be the corresponding control law attaining it. Let f : R → R, o : Z → R,
and constant m be defined as follows: f is a strictly monotonically increasing continuous
function such that f(infα∈A J∗(a)) > 0; o is any function such that limt→∞ o(t)t−θ is a
positive finite number for some θ ∈ (0, 1); and m is any integer such that m > |S|+ 1.For
our implementation purposes we take f as the logarithmic function and o(t) as the function
o(t) = 2
√
(t), for which θ = 0.5. The value of m can be satisfactorily chosen depend-
ing on the cardinality of the state space. The adaptive controller consists of two separate
operations, estimation and control:
• Estimator: At each time step 0, m, 2m, 3m, ..km, (k + 1)m, ..., estimate α by
αˆt := argmaxa∈AD¯t(α), (2.12)
where
D¯t(α) := K
∏
(i,j,u)∈F c
p(i, j, u, α)nt(i,j,u), (2.13)
3In this section, p(i, j, u, α) denotes pij(u) when the model α has been selected.
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K =
[
1
f {J∗(α)}
]o(t)
, (2.14)
and F c is the complement of the set of forbidden transitions F , which is assumed to
be known a priori. These transitions correspond to zero values for p(i, j, u, α). In
(2.13), nt(i, j, u) is defined as
nt(i, j, u) = 1 +
t−1∑
s=0
1(zs = i, zs+1 = j, us = u) (2.15)
and can be interpreted as measuring the number of times a transition occurs from i
to j under control u. Here 1(.) denotes the indicator function. At time km, knowing
the parameter estimate ˆαkm, we can find the optimal cost function J∗( ˆαkm) and the
optimal control law φ(zt, ˆαkm) which will be used for the next m time steps. The
parameter estimate is kept constant at ˆαkm between time steps km and (k+1)m−1.
• Controller: At each time t, the control applied is
ut := φ(zt, αˆt). (2.16)
The optimal cost function and optimal control law are determined by applying policy iter-
ation to the estimated model.
Remark 2. The adaptive algorithm presented here is based on the transition probability
expression (2.2). Since this expression accurately models an instantaneously random PBN,
it is only to be expected that performance degradation will occur as the value of q is reduced
from 1 to 0. This will be borne out by our simulations in the next section.
Remark 3. From a practical point of view, the expectation is that the constituent Boolean
networks of a PBN switch very infrequently. In other words, the value of q can be reason-
ably assumed to be very small. In such a scenario, one could consider each constituent
Boolean network to be a possible model to be identified by the estimation algorithm. Al-
though this increases the cardinality of the set of possible models, it is expected to result
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in improved performance especially since a small value of q means that the constituent
networks will change very infrequently so that the estimation algorithm will have enough
time to identify the current Boolean network. This will also be borne out by the simulation
results in the chapter.
B. Algorithms
The schematic diagram of the adaptive control algorithm is shown in Fig. 5. The controller
and estimator modules are shown separately with the model set A for the estimator module
explicitly indicated. Two different choices for the model set A will lead to the two different
algorithms presented in this chapter. The family of PBNs is shown schematically in Fig.
6.Each member of the family consists of a number of constituent BNps. The underlying
PBN is assumed to come from the family. Any switching from one underlying PBN to
another is assumed to be deterministic and very infrequent so that, for all practical purposes,
the estimator does not need to track a model changing with time.
1. Algorithm 1
In Algorithm 1, we assume that the family of PBNs constitutes the model set A. Note that
this formulation encompasses context-sensitive PBNs, instantaneously random PBNs, and
BNs with perturbation (BNps) as they are all special cases of PBNs. For each model (PBN),
we can compute the transition probability matrix for the extended state space using Eqn.
2.2, but it is very difficult to determine the context number from the output state data of
the actual PBN. So, constructing the transition counter matrix for the extended state space
is practically impossible. For example, suppose each PBN consists of 4 contexts (4 BNps)
and the actual underlying PBN is the 2nd PBN in the model set. In addition, suppose at time
t there is a transition from state 5 of BNp2 (i.e, context 2) to state 8 of BNp3 (i.e, context
3). In that case, we will observe the 5 → 8 transition; however, in the transition counter
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Fig. 5. Adaptive Control Algorithm.
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Fig. 6. Family of Probabilistic Boolean Networks.
matrix there would be 16 elements for that particular 5 → 8 transition (corresponding to
the different combinations of 4 source contexts and 4 destination contexts) and there is no
way of figuring out which precise context switching occurred. Faced with this hurdle, we
compress the transition probability matrix in such a way so that we don’t need to find the
extended transition counter matrix. This can be done by using equation 2.2, where the
individual transition probability matrices for the different contexts have been averaged out.
This averaging out causes no loss of context information when the PBN is instantaneously
random since in that case there is no context information to start with; however, even
when the PBN is not instantaneously random, and context information is lost, we can still
use the averaged transition probability matrix to estimate the model (PBN) number of the
underlying PBN. Such an algorithm using the averaged transition probability matrix will
henceforth be referred to as Algorithm 1. Clearly, one would expect such an algorithm to
perform well for q = 1 (i.e, instantaneously random PBN) with performance degradation
occurring as the value of q is reduced (i.e, we are moving further and further away from an
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instantaneously random PBN.)
2. Algorithm 2
The main problem with Algorithm 1 is that for small values of the switching probability q
(which are typically the more realistic ones), it doesn’t perform well. The attractor basin
structures of the different constituent BNps of a particular PBN vary significantly and so,
averaging of the transition probability matrices of the different constituent BNps is not an
appropriate strategy for context-sensitive PBNs with low switching probabilities. For that
situation, we can consider the other extreme scenario, where q = 0. Then the context-
sensitive PBN reduces to a single BNp. A natural question that arises in trying to estimate
the underlying PBN from the state transition data is which form of the transition probability
matrix should be used. A reasonable answer for q = 0 would be to use the individual
transition probability matrix for each BNp. This significantly increases the cardinality of
the model space A and leads to Algorithm 2. For instance, if we have 4 constituent BNps
for each PBN as in Fig. 6, then the cardinality of the model space A will be increased by
a factor of 4. Algorithm 2 assumes no context switching and uses the set of constituent
BNps as the model set A. This set is used to estimate the model number and the stationary
control policy is determined using the policy iteration algorithm. Using simulations it will
be shown that Algorithm 2 works better than Algorithm 1 for small values of q. This is
quite intuitive because we estimate the model number only after a time interval of m, and
if the switching probability q is low, then the number of context switchings inside one
estimation time window is expected to be quite low. So, our assumption about the BNp not
changing within an estimation window is reasonable. In the next section we will discuss
the simulation results for two different sets of data and compare the performance of the two
algorithms for three different values of q.
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C. Examples
In this section, we present simulations to demonstrate the efficacy of the proposed adaptive
intervention strategies. Such simulation studies are especially important since the theoret-
ical results in [26] guarantee only almost sure convergence and, that in a Cesaro sense4.
We will consider two different examples of genetic regulatory networks. The first will be
an artificial example and the second will be a network derived from gene expression data
collected in a metastatic melanoma study. In each case, we will carry out simulation studies
using the previously discussed algorithms.
1. Artificial example
We consider a 4-gene network modeled by an unknown member of a known family of
context-sensitive PBNs. We assume that the cardinality of this family is 7, for each member
in this family we have 4 constituent BNps, and p = 0.01. The value of q will be chosen
differently for various simulations. Since gene values are binary, the cardinality of the
state space is 16. Without loss of generality, we assume that the first gene, i.e, the gene
corresponding to the most significant bit (MSB) in the gene activity profile, is the gene that
needs to be down-regulated, i.e, set to 0. We assume that the second gene is the control
gene that can be flipped, with u = 1 and u = 0 denoting the flipping and no flipping
actions, respectively. To adaptively intervene in the network, we choose m = 32. The cost
of control is assumed to be 0.5 and the states are assigned penalties as follows:
g˜(u, j) =


5 if u = 0 and MSB is 1 for state j
5.5 if u = 1 and MSB is 1 for state j
0.5 if u = 1 and MSB is 0 for state j
0 if u = 0 and MSB is 0 for state j
4Roughly speaking, convergence in the Cesaro sense formalizes the notion of conver-
gence of the time average of a signal. This clearly doesn’t imply pointwise convergence.
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Since our objective is to down-regulate the MSB gene, a higher penalty is assigned for
destination states having the MSB gene up-regulated. Also for a given MSB gene status for
the destination state, a higher penalty is assigned when the control is active versus when it
is not. We want to examine how algorithm 1 performs when the true model is deterministi-
cally switched. Accordingly, we set up the simulation with the actual model being switched
from PBN2 (model number 2) to PBN6 (model number 6) at the 10th estimation window
(time = 320). The switching probability (q) is 0.01. This emulates a context-sensitive PBN.
Fig. 7 shows the convergence results. Each of the following figures shows model and cost
comparisons between the non-adaptive regular controller (with complete model informa-
tion) and the adaptive controller. The top plot shows the estimated and actual models as
functions of the estimation time steps. The x-axis is calibrated in terms of the number of
estimation windows with each window being 32 time steps long. Similarly, the bottom
plot in each of the convergence figures shows the comparison of the cumulative adaptive
average cost and the cumulative non-adaptive average cost (assuming perfect knowledge
about the true model).From Fig. 7, it is clear that the estimated model converges to the true
model and the cumulative adaptive average cost goes towards the cumulative non-adaptive
average cost. Fig. 8 shows the simulation results obtained using algorithm 2 on the same
simulation set up as above with q = 0.01. Clearly, the estimated model converges to the true
model and the cumulative adaptive average cost converges to the cumulative non-adaptive
average cost for the true model. The estimated model convergence in the case of algorithm
2 is much faster than that obtained using algorithm 1. This is to be expected since, with
q = 0.01, the underlying assumptions for algorithm 2 are a better fit to the real scenario.
We next study the effect of the value of q on the performance of the two algorithms. To
compare the two algorithms, we cannot rely on just one simulation. Moreover, we are more
interested in achieving controlled cost convergence rather than model convergence as our
sole aim in intervention is to minimize the long term average cost. Accordingly, we run
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Fig. 7. Artificial Example:Algorithm 1.
Fig. 8. Artificial Example: Algorithm 2.
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the same simulation one hundred times and calculate the difference between the cumula-
tive adaptive and cumulative non-adaptive average costs in each case. We then average the
difference sequence over the 100 simulations. Fig. 9 shows the results for 30 estimation
windows (time = 960) for three different values of q.From Fig. 9, we see that the results
match our intuition: algorithm 1 works well for q = 1 (instantaneously random PBN)
whereas when q is low or 0, algorithm 2 works better.
Fig. 9. Artificial Example: Cost Difference Comparison of the two Algorithms for different
values of q.
2. Melanoma application
In a study of metastatic melanoma it was found that experimentally increasing the levels
of the Wnt5a protein secreted by a melanoma cell line via genetic engineering methods di-
rectly altered the metastatic competence online as measured by the standard in vitro assays
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for metastasis [35]. Furthermore, it was found that an intervention that blocked the Wnt5a
protein from activating its receptor, the use of an antibody that binds the Wnt5a protein,
could substantially reduce Wnt5a’s ability to induce a metastatic phenotype. This suggests
a control strategy that reduces the WNT5A gene’s action in affecting biological regula-
tion, since the data suggest that disruption of this influence could reduce the chance of a
melanoma metastasizing, a desirable outcome. PBNs derived from the same expression
data have been used in [15, 16, 17, 34] for demonstrating earlier non-adaptive intervention
strategies. We consider 7-gene PBNs containing the genes WNT5A, pirin, S100P, RET1,
MART1, HADHB and STC2 obtained via the algorithms described in [27]. The states are
ordered as above, with WNT5A as the most significant bit (MSB) and STC2 as the least
significant bit (LSB).
We have constructed 7 PBNs with four constituent BNs in each. The adaptive in-
tervention strategy has been applied to the family of PBNs with pirin as the control gene
(u = 1, state of pirin is reversed, and u = 0, no intervention), m = 256, and p = 0.01.
The value of q varies between simulations. The cost of control is assumed to be 0.5 and the
states are assigned penalties as follows:
g˜(u, j) =


5 if u = 0 and WNT5A is 1 for state j
5.5 if u = 1 and WNT5A is 1 for state j
0.5 if u = 1 and WNT5A is 0 for state j
0 if u = 0 and WNT5A is 0 for state j
Since our objective is to down-regulate the WNT5A gene, a higher penalty is assigned for
destination states having WNT5a up-regulated. Also, for a given WNT5A status for the
destination state, a higher penalty is assigned when the control is active versus when it is
not. Figs. 10 and 11 show the performance of the adaptive intervention schemes using
algorithms 1 and 2, respectively. In each case, the genetic regulatory network is initially
described by PBN4 (model number 4) and at estimation window number 10 (corresponding
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to time =2560), the underlying model is deterministically switched to PBN2 (model num-
ber 2). The switching probability (q) is assumed to be 0.01. From the model convergence
plots in Figs. 10 and 11, it is clear that the estimated models track the actual model quite
well. Furthermore, the model tracking using algorithm 2 is better than with algorithm 1.
This is consistent with our expectation since for the small q, the underlying assumption for
algorithm 2 represents a closer approximation to reality. The cumulative adaptive average
costs also appear to converge to the non-adaptive ones. To see if these results are rep-
Fig. 10. Melanoma Application: Algorithm 1.
resentative, we ran the same simulation one hundred times and calculated the differences
between the cumulative adaptive and non-adaptive costs for each of the two algorithms.We
then averaged the difference sequence over the one hundred simulations. Fig. 12 shows
the plots of the average difference sequence over 30 estimation windows (time = 7680) for
three different values of the switching probability q. From the figure, we see that the re-
sults match our intuition: algorithm 1 works well for q = 1 (instantaneously random PBN)
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Fig. 11. Melanoma Application: Algorithm 2.
whereas when q is low or 0, algorithm 2 works better.
D. Concluding remarks
We have demonstrated the feasibility of applying adaptive intervention to improve interven-
tion performance in genetic regulatory networks modeled by PBNs. Specifically, we have
shown via simulations that when the network is modeled by a member of a known family
of PBNs, one can use adaptation and carry out a certainty equivalence design that leads to
improved performance in terms of the average cost. These simulation studies are important
since the theoretical results in the literature guarantee only almost sure convergence and,
that too, in the Cesaro sense. We have presented two different algorithms for model estima-
tion, and argued that while one of the algorithms is well suited for instantaneously random
PBNs, the other is much better for context-sensitive PBNs with low switching probability
between the constituent BNs. Our simulation results confirm these intuitive expectations.
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Fig. 12. Melanoma Application: Cost difference comparison of the two algorithms for dif-
ferent values of q.
Though mathematically the intervention strategy is close to optimal, there are some seri-
ous problems associated with this approach. Estimating the transition probability matrix
(TPM) of a probabilistic Boolean network and practical feasibility of switching control are
two of the major impediments. This motivates the introduction in CHAPTER III of a new
approach for constructing networks consistent with prior biological knowledge. We will
focus mostly on Boolean Networks because the parameters in a stochastic model are dif-
ficult to estimate, given the paucity of biological data. In CHAPTER IV, some real world
examples are used to introduce practically feasible intervention strategies.
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CHAPTER III
FROM PATHWAYS TO NETWORKS*
This chapter develops a general theoretical framework for arriving at genetic regula-
tory networks whose state transitions realize a set of given biological pathways or minor
variations thereof. Often in biology, the a priori or expert knowledge is presented in the
form of signaling pathways. Although such pathway information can be useful, it fails to
capture the multivariate interactions between the genes. Interventions based on univariate
gene interactions captured in pathways often fail to achieve the intended effects. In addi-
tion, it is quite common to have information on multiple pathways that may share some
common nodes. In such a case, each pathway attempts to capture the intergene relation-
ships when restricted to the genes in that pathway, but provides no information about the
global interaction between the genes involved in the different pathways other than putting
the constraint that the global interactions, when restricted to a particular pathway, must
satisfy the relationships mandated by that pathway.
The problem of piecing together an overall underlying genetic regulatory network
structure given (partial) pathway information is, therefore, very important in all areas of
biology. However, to our knowledge, thus far the problem has not even been formulated
properly, let alone be solved. Perhaps, one reason for this is the absence of a wide enough
realization that pathway knowledge, no matter how appealing it may be, constitutes only
partial knowledge restricted to a particular context. We next further motivate the work pre-
sented here by using a specific application area and its research needs.
In recent years, there has been considerable interest in the area of Genomic Signal Pro-
*Part of this chapter is reprinted with permission from “From biological pathways to
regulatory networks ” by Ritwik K. Layek , Aniruddha Datta and Edward R. Dougherty,
2011, Mol. BioSyst., vol. 7, pp. 843-851, Copyright [2011], Royal Society of Chemistry.
(http://pubs.rsc.org/en/content/articlelanding/2011/mb/c0mb00263a)
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cessing [36, 37] which seeks to mathematically model the multivariate interactions between
the genes and utilize these models to not only differentiate between normal and abnormal
(diseased) behavior but also to suggest appropriate therapeutic interventions in the case
of the latter. The principal motivation for this is the growing realization that in the case
of complex diseases such as cancer, therapeutic approaches based on simplistic marginal
modeling, as in the case of biological pathways, can at best achieve modest success. To cap-
ture the holistic behavior of the genes, one can use genetic regulatory networks instead of
working with only pathway knowledge. To date, genetic regulatory network modeling has
been carried out using various approaches such as differential equations and their discrete-
time counterparts [38, 39, 40, 41], Bayesian networks [42, 43, 44, 45], Boolean networks
[46, 47, 18],[48, 49, 50, 51, 52, 45, 53, 54, 55], and their probabilistic generalizations, the
probabilistic Boolean networks (PBNs) [19, 20, 21]. PBNs have also found extensive use
in the design of intervention approaches that seek to slow down or halt disease progression
[37, 56, 57, 58, 59, 60, 61, 32, 62, 63, 17, 64].
Most of the intervention approaches developed thus far for PBNs make use of the fact
that the state transitions in a PBN can be modeled as a Markovian process. Estimating the
transition probabilities for such a process, which is by no means a straight forward task,
is an essential pre-requisite for the successful application of most of these intervention ap-
proaches. Although a handful of these schemes [61, 32] are able to bypass the need for es-
timating the transition probability matrix, none of them are capable of incorporating prior
biological pathway information into the network design. This is a significant drawback
since most of the prior biological knowledge in the literature resides in the form of bio-
logical pathways, gleaned as empirical observations across different experiments. Indeed,
the accuracy of genetic regulatory networks and the data requirements for their inference
could be greatly improved by developing a mechanism to incorporate pathway knowledge
into the network itself. This chapter develops a systematic procedure for doing precisely
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that for the case of Boolean networks. Here, it is appropriate to point out that earlier work
has focussed on generating Boolean networks satisfying principally attractor constraints
[27, 65]. The results presented here are more general and essentially subsume the earlier
ones.
This chapter is organized as follows. In section A, we introduce some notation and
present the basics of digital design. In section B, we present a simple example to demon-
strate how one can use pathway knowledge and Karnaugh maps to generate a family of
BNs whose trajectories realize the given pathways. In section C, the general procedure for
synthesizing Boolean network from a set of pathways is presented. In section D, the simple
example of section B is revisited and solved using the algorithm developed in section C. In
section E, we impose additional attractor constraints on the family of BNs to facilitate the
choice of a particular BN. In section F, we apply the results of this chapter to the widely
studied p53 pathway and demonstrate that the resulting network exhibits dynamic behavior
consistent with experimental observations from the published literature. Finally, section G
contains some concluding remarks.
A. Notation and digital design basics
1. Boolean networks
A Boolean Network (BN), Υ = (V, F ), on n genes is defined by a set of nodes/genes
V = {x1, ..., xn}, xi ∈ {0, 1}, i = 1, ..., n, and a list F = (f1, ..., fn), of Boolean functions,
fi : {0, 1}
n → {0, 1}, i = 1, ..., n [18]. The expression of each gene is quantized to two
levels, and each node xi represents the state/expression of the gene xi, where xi = 0 means
that gene i is OFF and xi = 1 means that gene i is ON. The function fi is called the
predictor function for gene i . Updating the states of all genes in Υ is done synchronously
at every time step according to their predictor functions. At time t, the network state is
given by x(t) = (x1(t), x2(t), ..., xn(t)), called a gene activity profile (GAP).
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2. Karnaugh map representation of Boolean networks
The subsequent development in this chapter relies heavily on the Karnaugh Map (K-map)[66]
representation of a Boolean function. Consequently, let us now briefly introduce Karnaugh
Maps and demonstrate their utility in digital design. Consider an arbitrary Boolean Net-
work on three genes A, B and C with the following three Boolean update rules:
Anext = B + C
Bnext = AC¯ (3.1)
Cnext = A+ B¯.
Here Anext, Bnext and Cnext denote the values of A, B and C at the next time step. Al-
though the above rules represent the Boolean network in a compact form, they do not permit
ready visualization of the state transitions or the attractors. Such ready visualization can be
achieved by equivalently representing Equation (3.1) using the truth table shown in Table
IV or the state transition diagram shown in Fig. 13.
Note, however, that the information contained in the truth table or the state transition
diagram would not allow one to directly arrive at the Boolean update rules in Equation (3.1)
which is what would be required if one were trying to realize the network using logic gates.
This synthesis of Boolean functions from the truth table is facilitated by Karnaugh maps.
In a Karnaugh Map, each current state is represented by a square and two neighboring
squares have a Hamming distance of unity. This is crucial because this Hamming distance
separation enables us to cluster large blocks of size 2m in the maps. For each current state
(represented by a square), the value of the particular gene in the next state is written inside
the square. As an example, the three Karnaugh Maps for the Boolean Network correspond-
ing to the three update rules in Equation (3.1) are shown in Fig 14. Since we have three
genes with expressions which can only be binary, there is a total of eight states and hence
eight squares in each Karnaugh map. For a moment, let us focus attention on the K-map for
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Table IV. Truth Table of the Boolean Network (Eqn. 3.1).
A(n) B(n) C(n) A(n+1) B(n+1) C(n+1)
0 0 0 0 0 1
0 0 1 1 0 1
0 1 0 1 0 0
0 1 1 1 0 0
1 0 0 0 1 1
1 0 1 1 0 1
1 1 0 1 1 1
1 1 1 1 0 1
0 0 0 1 1
0
0 0
1
1 1 1
1
0
1
0
1
0
0
1 11
0 0
= +
=
= +
Fig. 13. State transition diagram of the Boolean Network (Eqn. 3.1).
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Fig. 14. Karnaugh map representation of Table IV.
gene A, denoted by Anext in Fig. 14. The possible gene value combinations for the current
time step are shown to the left (genes A and B) and to the top (gene C) of the K-map. Also
it should be noted that the bottom two rows of the K-map correspond to A = 1, the middle
two rows correspond to B = 1 and the rightmost column corresponds to C = 1, all in the
current state.
Define a minterm as a Boolean product (‘AND’ function) where each gene or its com-
plement occurs exactly once. A three gene network, having exactly eight states, will have
eight possible minterms, and each square in the Karnaugh map is the support of a unique
minterm. For instance the square corresponding to the state 010 is the support of the unique
minterm A¯BC¯ (the Boolean product A¯BC¯ = 1 if and only if the state is 010).
We next use this three gene example to show how the Karnaugh map representation
can help us in arriving at the Boolean functions for the update rules. Let us focus on the
K-map for gene B, i.e. Bnext in Fig. 14. In this K-map, two of the minterms giving
Bnext = 1 are ABC¯ and AB¯C¯. By summing (‘OR’ing) the minterms having functional
value 1 (the value inside the squares), we can generate the network functions. For example,
Bnext = ABC¯ + AB¯C¯ = AC¯. In the K-map, this can be done geometrically. As, the two
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neighboring states (squares) have a hamming distance of 1, we can remove the variable
that differs between the corresponding minterms to more compactly represent the set of
two squares. In the K-map of Bnext, the states corresponding to Bnext = 1 are 110 and
100 and their hamming distance is 1. So, the product term representing the two states is
simply AC¯ (We remove the variable B as both B and its complement B¯ appear in the two
minterms ABC¯ and AB¯C¯ and, therefore, B is a non-essential variable). The idea that we
have just illustrated for clustering two minterms in the K-map can be extended to cluster
additional minterms and obtain a minimal realization of the Boolean function in question.
Indeed, this procedure is used extensively in computer architecture and digital design [67].
In this chapter we will follow the clustering of minterms approach which will give us
the minimal SoP or Sum of Products (‘OR’ of ‘AND’s) form of the Boolean functions [67].
The prior knowledge presented in the form of signalling pathways will furnish us with par-
tially filled Karnaugh Maps for updating each of the genes. Clearly, such a partially filled
Karnaugh Map will not yield a unique Boolean function, even in the Sum-of-Products form,
so that instead of arriving at a unique Boolean network, we may end up with a family of
Boolean networks. On the other hand, different pathways may introduce conflicts in the
Karnaugh Map describing the update of a particular gene, in which case it would be impos-
sible to arrive at a Boolean network to simultaneously satisfy all the pathway constraints.
Fortunately, in such a case, the pathway constraints can be relaxed since (i) pathways only
represent empirical observations across different experiments; and (ii) there is no accurate
timing information to go with the pathways, which means that the initially assumed timing
information in the pathways can be slightly altered to facilitate a solution. In this chap-
ter, we will formally develop these ideas and present a systematic solution to the problem
of generating a family of Boolean networks whose trajectories satisfy given pathways or
minor variations thereof. For clarity of presentation, we first begin with a simple example
which can be handled in an intuitive way without having to invoke the complete machinery
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to be developed for the general case.
B. From pathways to a family of BNs: a simple example
For clarity of presentation, consider a Boolean Network (BN) on 4 genes A,B,C & D so
that each state (or GAP) is given by a binary vector of the form V = abcd, where a, b, c, d
are either 0 or 1. Define the term pathway segment A t:a,b−→ B to mean that if gene A as-
sumes the value a then gene B transitions to b in no more than t subsequent time steps. A
pathway is defined to be a sequence of pathway segments of the form A t1:a,b−→ B t2:b,c−→ C. In
the above pathway, there are two pathway segments A t1:a,b−→ B and B t2:b,c−→ C. We define a
trajectory to be a sequence of states V0 → V1 → V2 → V3 → V4 resulting from the network
rules beginning at some initial state . Clearly, a trajectory provides a more complete picture
of the dynamic evolution of the BN resulting from the multivariate interactions between
the genes. Pathway information, on the other hand, is neither regulatory nor state space
knowledge; it is marginal and incomplete.
Given the wide prevelance of apriori biological knowledge in the form of pathway
information, an important problem to consider is how to generate a BN whose trajectories
are consistent with a given set of pathways. This is an ill-posed inverse problem that could
have multiple solutions or perhaps none. Therefore, our objective will be to investigate and
devise an algorithm to generate the set of all possible Boolean networks and to find out the
minor required timing or functional perturbation of the pathways if no Boolean network
can be found to satisfy the set of pathway constraints. We will do a structural analysis for
the Boolean Network synthesis problem. This is a brute force exhaustive procedure but can
be used to generate the complete set of admissible BNs. Later the BN set can be shrunk by
imposing various realistic constraints such as (i) an upper bound on the number of predic-
tors per gene; (ii) an upper bound on the number of attractors; (iii) steady state distribution
of the attractors from actual experiments (e.g, Microarray Experiments); (iv) concordance
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with experimentally measured time series dynamics (e.g, those obtained using Green Flu-
orescent Protein based techniques), and so on. We next use a simple four-gene network to
illustrate the key ideas behind the exhaustive search procedure.
We have chosen an example with four genes since four is the largest number for which
the Karnaugh map can be visualized in two dimensions. For larger networks, the underly-
ing philosophy is the same although one would have to resort to computer programming.
Now let us assume that we are given three pathways: A 1:1,1−→ B 1:1,1−→ D, A 1:1,0−→ C and
C
1:1,0
−→ D. First, we solve the inverse problem for pathway 1; thereafter, we add pathways
2 and 3, respectively, and shrink the solution space.
State space Realization of pathways
Pathway 1 (A 1:1,1−→ B 1:1,1−→ D): There are two segments to this pathway. The first segment
A
1:1,1
−→ B mandates that if the current state has A = 1, then it will transition to a state
with B = 1 in one time step. So the state transition consistent with the pathway informa-
tion is 1xxx→x1xx1. Similarly, B 1:1,1−→ D translates to the state transition x1xx→xxx1.
These are the only state transition constraints mandated by pathway 1. These state transi-
tion constraints can be represented in the Karnaugh Map for the individual genes as follows.
Apw1next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D B
pw1
next:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D C
pw1
next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D D
pw1
next:
x x
1 1
xx
11
x x
1 1
xx
11
A
C
B
D
Here, the 4 Karnaugh Maps correspond to the truth tables for genes A,B,C and D in the
next time step as a function of the current state. As before, the bottom two rows correspond
to A = 1, the middle two rows correspond to B = 1, the right two columns correspond to
1Here ’x’ denotes a gene value that could be either 0 or 1.
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C = 1 and the middle two columns correspond to D = 1, all in the current state. Also, the
superscript pw1 indicates that these K-maps correspond to pathway 1.
Clearly we see that the value of gene A at the next time step does not depend on what
the current state is. In the case of gene B, if the current state is 1xxx (meaning A = 1),
then the next state will be x1xx (meaning B = 1). This is shown in the K-map for gene
B where the bottom two rows are filled with 1s and the remaining 8 entries are either 0 or
1. Similarly the value of gene C at the next time step does not depend on the current state
while the value of geneD at the next time step depends only on the current value ofB. The
above K-maps characterize the entire family of BNs satisfying the constraints mandated by
pathway 1.
Pathway 2 (A 1:1,0−→ C): If we solve separately for pathway 2, we get another set of K-maps
for each of the genes A, B, C and D. The K-maps are shown below.
Apw2next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D B
pw2
next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D C
pw2
next:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D D
pw2
next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D
Next we would like to merge the two sets of K-maps to obtain K-maps consistent with
both the pathways 1 and 2. The solution set is shown below.
Anext:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D Bnext:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D Cnext:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D Dnext:
x x
1 1
xx
11
x x
1 1
xx
11
A
C
B
D
Pathway 3 (C 1:1,0−→ D): If we solve separately for pathway 3, we get another set of K-
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maps for each of the genes A, B, C and D. The K-maps are shown below.
Apw3next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D B
pw3
next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D C
pw3
next:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D D
pw3
next:
x x
x x
00
00
x x
x x
00
00
A
C
B
D
Clearly, for genes A, B and C, there is no conflict between the two sets of K-maps and
we can easily merge them to get the K-maps shown below.
Anext:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D Bnext:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D Cnext:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D
On the other hand, the two K-maps for gene D are in conflict as evident from the K-maps
given below.
Dpw1next:
x x
1 1
xx
11
x x
1 1
xx
11
A
C
B
D




Dpw3next:
x x
x x
00
00
x x
x x
00
00
A
C
B
D




The conflict occurs when the current state is x11x (see the entries inside the two circles).
This conflict is not at all surprising: if the current state is x11x then B = 1 will try to force
D = 1 at the next time step as per pathway 1 while C = 1 will try to simultaneously force
D = 0 in accordance with pathway 3. One way to resolve the conflict would be to decide
in favor of one of the two requirements. Let us assume (without loss of generality) that A
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has higher priority than B and B has higher priority than C, and so on. In that case, gene
B will affect the state transition earlier than gene C. Accordingly, we decide that in the
above conflict, x11x will transition to xxx1 in the next time step so that the K-map of D
gets modified as according to the K-map below.
Dnext:
x x
1 1
00
11
x x
1 1
00
11
A
C
B
D
 
 
However, we still need to satisfy pathway 3. Although it is not possible to meet both
pathway constraints in the same time step, we can relax the timing of the third pathway
as C
2:1,0
−→ D, which means that C = 1 will lead to D = 0 in no more than 2 time steps.
Accordingly, x11x will transition to xxx0 in no more than two time steps. Thus, the com-
plete transition will be x11x→ xxx1→ xxx0. However, we know from the merged K-map
of D (after conflict elimination), that only x01x leads to xxx0 in one time step (see the
two semicircles in the above K-map where the value is 0). Hence, the second state in the
above state transition becomes x011, leading to the actual state transitions x11x→ x011→
xxx0. This set of two state transitions yields two new pathways: pathway 4 : BC 1:1,0−→ B
and pathway 5: BC 1:1,1−→ C. The introduction of these two new pathways will lead to the
iterative update of the K-maps until the K-maps converge to a stable set of BNs.
1. Iterative update of K-maps
Now, pathways 4 and 5 mandate that whenever the current state becomes x11x, the next
state will be x011 which means that gene B = 1 and gene C = 1 will lead to gene B = 0
and gene C = 1 in the next time step. This again conflicts with the earlier K-maps of genes
B and C.
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Conflict in K-map of gene B: If the current state is 111x, then a conflict arises in the K-
map of gene B. Specifically, A = 1 in the current state mandates B = 1 in the next state,
whereas BC = 1 in the current state mandates B = 0 in the next state.The conflicting
Karnaugh Maps for these two cases are shown below along with the marked conflict zone.
Bnext:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D




	
Bpw4next:
x x
x x
xx
00
x x
x x
xx
00
A
C
B
D




	
As before, we once again apply the conflict resolution rule. We set B = 1 in the next
state when BC = 1 in the current state to obtain the modified K-map for gene B shown
below.
Bnext:
x x
x x
xx
00
1 1
1 1
11
11
A
C
B
D




	
This mandates the state transition: 111x→x1xx. As before, we have to relax the timing
constraint of pathway 4: BC 1:1,0−→ B is changed to BC 2:1,0−→ B. Consequently, the state
x1xx has to be followed by the state x0xx. However, we know that a necessary condition
for B = 0 in the next state is that A = 0 in the current state. So, we get another new
pathway, pathway 6: ABC 1:1,0−→ A. It is clear that although the original three pathways
did not yield any update rules for gene A, the conflict resolution rules that we have applied
have given rise to a new reverse pathway which imposes an update rule on gene A.
Conflict in K-map of gene C: If the current state is 111x, then a conflict arises in the
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K-map of gene C as well. Specifically, A = 1 in the current state mandates C = 0 in the
next state, whereas BC = 1 in the current state mandates C = 1 in the next state. The con-
flicting K-maps for these two cases are shown below along with the marked zone of conflict.
Cnext:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D




	
Cpw5next:
x x
x x
xx
11
x x
x x
xx
11
A
C
B
D




	
As before, we once again apply the same conflict resolution rule. We set C = 0 in the
next state when A = 1 in the current state to obtain the modified K-map for gene C shown
below.
Cnext:
x x
x x
xx
11
0 0
0 0
00
00
A
C
B
D




	
This mandates the state transition: 111x→xx0x. As before, we have to relax the timing
constraint of pathway 5: BC 1:1,1−→ C is changed to: BC 2:1,1−→ C. Consequently, the state
xx0x has to be followed by the state xx1x. However, we know that a necessary condition for
C = 1 in the next state is that A = 0 in the current state. This leads to the same pathway 6
:ABC
1:1,0
−→ A, as before. Fortunately, in this simple example, the conflict resolutions in the
K-maps ofB and C both lead to the same pathway 6. This means that wheneverABC = 1,
the next state will be 0xxx. Accordingly, the K-map of gene A is modified as shown below.
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Anext:
x x
x x
xx
xx
x x
x x
xx
00
A
C
B
D
Finally we have reached a stage where there are no more conflicts in the K-maps and the
final K-maps are shown below.
Anext:
x x
x x
xx
xx
x x
x x
xx
00
A
C
B
D Bnext:
x x
x x
xx
00
1 1
1 1
11
11
A
C
B
D Cnext:
x x
x x
xx
11
0 0
0 0
00
00
A
C
B
D Dnext:
x x
1 1
00
11
x x
1 1
00
11
A
C
B
D
Thus, with minor modifications of the third original pathway, we have solved the inverse
problem of finding the class of Boolean Networks. The procedure can be extended to find
the complete set of BNs consistent with any number of given pathways. In this problem, we
can see the shrinkage in the number of possible Boolean networks. To start with, the search
space had a cardinality of 264. After incorporating the pathway knowledge, the cardinality
of the search space shrinks to 230.
As we will see later, the cardinality of the search space can be further reduced by im-
posing constraints on the number and relative significance of the attractors, the connectivity
of the network, etc.
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C. From pathways to a family of BNs: the general procedure
1. Definitions and preliminary observations
In section B we defined a pathway and pathway segments only in terms of single genes.
The solution to the simple example presented there was also based on an intuitive proce-
dure. Our objective here is to develop a systematic general procedure which can yield a
Boolean network consistent with an arbitrary number of pathways. Towards this end, we
next introduce some definitions and make some preliminary observations.
For any Boolean function f , define the support of f , denoted by supp(f), to be the set
of all argument values that make f assume the value of 1. Also, for any Boolean function
S, and for a Boolean value s ∈ {0, 1}, define
Ss =


S if s = 1
S¯ if s = 0.
(3.2)
The function Ss defined in Eqn. 3.2 can be thought of as being the indicator function of the
set {x : S(x) = s}.
Let us now generalize the pathway segment definitions presented earlier:
1. A Simple Pathway Segment is defined as Y t1:a,b−→ B, where B is a single gene, Y
can be an arbitrary Boolean function and a, b ∈ {0, 1}. Unless otherwise indicated,
the term pathway segment in this chapter will refer to a simple pathway segment.
A simple pathway segment can be implemented using only the K-map of the target
gene, i.e. gene B in this case.
2. A composite pathway segment is defined as Y t2:y,z−→ Z where both Y and Z are
arbitrary Boolean functions and y, z ∈ {0, 1}. We next develop the theory for de-
composing a given composite pathway segment into a number of simple pathway
segments since only the latter are directly implementable using K-maps.
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Without any loss of generality, let us assume t2 = 1 in the above composite pathway
definition. Using Equation (3.2), the composite pathway segment Y 1:y,z−→ Z can be
alternatively written as Y 1:y,1−→ Zz.
Furthermore, Zz can be expressed in the minimal SOP (Sum of Products) form [67]:
Zz = P1 + P2 + · · ·+ Pk (3.3)
where each Pi, i = 1, 2, · · · , k is a Boolean product term of the form
Pi = A
i
1A
i
2 · · ·A
i
li
(3.4)
and each Aij is either a gene or its complement.
From the above analysis it is evident that Y 1:y,1−→ Pi =⇒ Y
1:y,1
−→ Zz (because Pi =
1 =⇒ Zz = 1). So, any Pi can replace Zz producing the desired pathway effect. For
the sake of simplicity we will choose the product term Pm having the least number
of genes. The resulting composite pathway segment Y 1:y,1−→ Pm can be decomposed
into lm simple pathway segments that have to be simultaneously satisfied:
Y
1:y,1
−→ Am1
Y
1:y,1
−→ Am2
Y
1:y,1
−→ Am3 (3.5)
.
.
.
Y
1:y,1
−→ Amlm .
Thus the K-map implementation of these lm simultaneous simple pathway segments
will provide a non-unique realization of the original composite pathway segment:
Y
1:y,z
−→ Z.
3. A pseudo pathway is defined to be any pathway that can be inferred from a given
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Table V. Priority Ordering
A ¯A B ¯B C ¯C D ¯D
Boolean network. The update rules for a Boolean network mandate that the state
(or GAP) transitions occur in a particular sequence. By marginally focusing on the
transitioning of particular components of the GAP, one can come up with inherent
pathway relationships, which we refer to as pseudo pathways.
2. Priority ordering between Boolean functions
In section B, we loosely introduced the notion of priority among genes for deciding which
gene would preferentially act on a target. Since different gene combinations, and not nec-
essarily individual genes, could be acting on a target, it is necessary to generalize the notion
to Boolean functions of genes. Such a generalization is carried out in this subsection by the
introduction of what we refer to as a priority index.
From biological understanding, we know that all genes do not influence a particular
target gene to the same extent. As an example, suppose genes A and B both influence the
status of target gene C in some way but with different relative abilities. Define priority as
the power of each gene to influence others in the pathway. Priority is a qualitative term and
cannot be used for conflict resolution unless we quantify it in some sense. Accordingly, we
next introduce a priority index which will be employed as the decision making parameter
in times of conflict resolution. Suppose that from our qualitative knowledge of genes and
pathways we can make a list of all the genes according to their powers. This is called the
priority list. As an example, suppose the priority list for the four genes A,B,C,D and
their complements A¯, B¯, C¯, D¯ are as shown in Table V:
Here A has the highest priority followed by A¯ and so on. Symbolically we write
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A > A¯ > B > B¯ > C > C¯ > D > D¯. We assume that the priority ordering is transitive
which means that if A > B and B > C, then A > C.
We next extend the notion of priority ordering between genes to that between product
terms and ultimately to that between two arbitrary Boolean functions. To do so, define the
priority index between two genes A and B by:
ρ(A,B) =


1 if A > B
0 if A < B.
Next we define the priority index between a product term Y = Y1Y2Y3Y4..Yl and a gene B
as:
ρ(Y,B) = 1/l
l∑
i=1
ρ(Yi, B). (3.6)
Finally we define the priority index between two product terms Y = Y1Y2Y3Y4..Yl and
Z = Z1Z2Z3Z4..Zk as:
ρ(Y, Z) =
1
k
k∑
j=1
ρ(Y, Zj)
=
1
kl
l∑
i=1
k∑
j=1
ρ(Yi, Zj). (3.7)
We next extend the priority index definition to the case of arbitrary Boolean functions
S1 and S2. To do so, we make use of the well known fact from Boolean algebra that any
Boolean function can be represented in a minimal Sum of Products (SoP) form. Suppose
the two functions S1 and S2 are expressed in such a form as:
S1 = P1 + P2 + P3 + · · ·+ Pn
S2 = Q1 +Q2 +Q3 + · · ·+Qn. (3.8)
Furthermore, suppose that Pi is the minimal product term in S1, i.e. the term having the
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minimum number of genes or gene’s complements. Consequently, Pi corresponds to the
maximum number of minterms (unit squares) in the K-map of S1. Similarly, assume that
Qj is the minimal product term in S2. The priority index between S1 and S2 is defined by
ρ(S1, S2) = ρ(Pi, Qj). (3.9)
The priority indices defined above satisfy the following properties:
0 ≤ ρ(S1, S2) ≤ 1
ρ(S1, S2) = 1− ρ(S2, S1). (3.10)
Based on the priority indices just defined, the priority ordering between two Boolean func-
tions S1 and S2 can be made as follows:
S1


> S2 if ρ(S1, S2) > 0.5
< S2 otherwise.
Before concluding this section on priority ordering, we mention that, as a general rule, if
we come across a composite pathway segment, then the highest priority will be given to ac-
commodate that. This is because a composite pathway segment gives rise to several simple
pathway segments that have to be simultaneously satisfied and, therefore, it is reasonable
to give it the highest priority.
3. Conflict and its resolution
In this subsection we generalize the conflict resolution procedure, introduced in section
B, to the case where we have an arbitrary number of genes and an arbitrary number of
pathways. Define a conflict as a situation when for a new pathway Y 1:y,b−→ B, where Y
is a Boolean function and B is a gene, there already exists a Boolean function Ψ with
supp(Ψ) ⊂ supp(Yy), supp(Ψ) 6= supp(Yy) such that Ψ
1:1,b¯
−→ B. We next explain how
such a conflict can arise.
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We have seen in section B that if the truth table mandated by a pathway segment does
not contradict the existing truth tables for the network (i.e, supp(Ψ) = ∅), then there is
no problem in incorporating such a pathway. However, if the demands of a new path-
way segment contradict the already existing truth table values (i.e, supp(Ψ) 6= ∅), then a
conflict arises. An adhoc procedure for resolving such a conflict for the simple example
was demonstrated in section B. Here we develop a systematic procedure for handling the
general case.
Suppose at a particular stage while determining an n-gene Boolean network satisfying
pathway information, we come to a new pathway segment Y 1:y,b−→ B where y, b ∈ {0, 1}.
This pathway segment can be implemented in the K-map for gene B. Specifically, we
would try to insert the value b in every minterm ∈ supp(Yy) in the K-map of gene B.
While doing so we may discover a set of minterms in supp(Yy) whose values are already b¯
in the K-map of gene B. We can combine the entire set of such minterms and sum them up
to obtain a Boolean function Ψ such that supp(Ψ) ⊂ supp(Yy). The situation is graphically
illustrated in Fig 15.
Clearly, in the above K-map of gene B, the minterms where YyΨ¯ = 1 can be unam-
biguously assigned the value of b. The conflict will arise in the subset supp(Ψ). Resolution
of this conflict will require us to determine the priority ordering between Yy and Ψ which
can be carried out by evaluating the priority norm between these two Boolean functions.
Depending on the priority ordering, we will adopt one of the two following options:
1. Yy > Ψ : In this case, Y
1:y,b
−→ B is given higher priority and all the minterms
∈ supp(Yy) will be assigned the value b. However, to satisfy the inherent pathway
segment Ψ 2:1,b¯−→ B, in the next time step, we generate another constraint. Clearly, to
get to the value of b¯ in the truth table of gene B, the trajectory would have to traverse
to the states which can lead to B = b¯ in one time step. So, the additional pathway
we obtain is a composite pathway segment: Ψ 1:1,1−→ S(b¯), where S(b¯) is a minimal
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Fig. 15. Conflict in K-map of gene B.
SoP set in the K-map of B having value b¯. That means this set inherits an already
implemented pseudo pathway S(b¯) 1:1,b¯−→ B which gets rid of the conflict. If, however,
no such S(b¯) can be found in the K-map of B, then the problem is unsolvable and
the algorithm is terminated.
2. Ψ > Yy : In this case, Ψ
1:1,b¯
−→ B is implemented first. The minterms ∈ supp(Ψ) will
be assigned the value b¯. However, to satisfy the other pathway segment in the next
time step, i.e. Y 2:y,b−→ B, we generate the other constraint. Clearly, to get to the value
b in the truth table of gene B, the trajectory has to traverse to the states in supp(Yy)∩
supp(Ψ¯). So, the additional pathway that we obtain out of this reasoning is: Ψ 1:1,1−→
YyΨ¯. This being a composite pathway segment, one would have to decompose it into
simple pathway segments before proceeding further.
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4. Total conflict and cyclic total conflict
In this subsection we wish to demonstrate conflict resolution in the extreme case when
supp(Ψ) = supp(Yy). This situation is called a total conflict and we denote it by the
notation
Y
1:y,b
։ B. Since in the case of a total conflict supp(Yy) ∩ supp(Ψ¯) = ∅, only the
first method presented in the previous subsection can be used. This is demonstrated in the
following example.
Example: Consider a 4 gene network with genes A,B,C,D so that each state (or
GAP) is given by a binary vector of the form V = abcd where a, b, c, d ∈ {0, 1}. Suppose
that gene B currently updates according to the Karnaugh map shown below.
Bnext:
1 1
1 1
00
xx
1 1
x x
00
00
A
C
B
D
Let us now introduce the new pathway segment AC 1:1,1−→ B. In the notation of section
3, Y = AC, b = 1 and Y1 = AC. Clearly the pseudo pathway we get from the Karnaugh
map corresponding to the minterms having AC = 1 is AC 1:1,0−→ B so that Ψ = AC. This is
a good example of a total conflict which cannot be resolved in a direct fashion. However,
examining the truth table of gene B, we get some useful information that could facilitate a
solution.
Without any loss of generality let us assume that whenever a total conflict arises, the
new pathway segment always gets the highest priority. Using this priority ordering, the
truth table of gene B is modified according to the K-map below.
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Bnext:
1 1
1 1
00
xx
1 1
x x
11
11
A
C
B
D
The minterms in this new truth table having value 0 are A¯B¯CD and A¯B¯CD¯ which can
be ‘OR’ed to get the product term A¯B¯C. So, the new composite pathway segment which
will resolve the total conflict is given by AC 1:1,1−→ A¯B¯C. This is a composite pathway
segment and will lead to three simple pathway segments: AC 1:1,1−→ A¯, AC 1:1,1−→ B¯ and
AC
1:1,1
−→ C which are to be implemented simultaneously.
Now it may happen that while trying to remove a total conflict A
1:a,b
։ B, we may ar-
rive at some other total conflicts like C
1:c,d
։ D , E
1:e,f
։ F, .. so on. These total conflicts and
their derivative total conflicts can be represented in a directed graph structure. The total
conflicts arising from the ordinary conflicts are the starting nodes of the graph. Then all the
derivative total conflicts will become the children of the corresponding parent nodes. We
can attempt to solve the total conflict problem in an iterative way by growing the graph.
This iteration will continue until either the graph is acyclic and converges to a solution
when there is no child node left, or the graph becomes cyclic, when we say that there is a
cyclic total conflict in the problem and the problem cannot be solved. These two situations
are depicted in Fig 16.
D. Simple example revisited
The adhoc solution to the small 4 gene BN synthesis example presented in section B was
mainly based on our intuition. We now apply the systematic procedure of the previous
section to the same example and highlight the differences. First, we point out that the
systematic procedure begins to deviate from the earlier adhoc one only from section C.
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Fig. 16. Solvability of the conflicting pathway problem.
Hence it is appropriate to start our analysis from there.
The adhoc treatment prior to section C tells us that the two new pathways 4 and 5
have to be satisfied simultaneously as otherwise the state transitions may not be the same
as desired. To ensure that, we assign the highest priority to the incorporation of the two
new pathways.
Iterative update of the truth tables: Recall that the K-maps for this example prior to
section B.1 are given by the K-maps below.
Anext:
x x
x x
xx
xx
x x
x x
xx
xx
A
C
B
D Bnext:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D Cnext:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D Dnext:
x x
1 1
00
11
x x
1 1
00
11
A
C
B
D
Also, the two pathways yet to be incorporated are pathway4 : BC 1:1,0−→ B and pathway5 :
BC
1:1,1
−→ C. These two pathways are to be solved simultaneously and with the highest
priority.
Conflict in the truth table of gene B: While trying to incorporate the simple pathway
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segment 4, we get the conflict shown below for gene B:
Bnext:
x x
x x
xx
xx
1 1
1 1
11
11
A
C
B
D




	
Bpw4next:
x x
x x
xx
00
x x
x x
xx
00
A
C
B
D




	
Using the notation introduced in section C.3, we have Y0 = BC and the new pathway
segment is Y0
1:1,0
−→ B. The conflicting function Ψ is given by Ψ = ABC. Clearly,
supp(Ψ) ⊂ supp(Y0). Since Y0 > Ψ, we put 0 in every minterm∈ supp(Y0) = supp(BC).
The resulting K-map is shown below.
Bnext:
x x
x x
xx
00
1 1
1 1
11
00
A
C
B
D




	
Next, we have to find a minimal set S(1) in the K-map which will suggest a new pathway
segment for resolving the conflict. To do this, the 1s in the K-map of B can be clustered as
shown below.
Bnext:
x x
x x
xx
00
1 1
1 1
11
00
A
C
B
D








	
From this clustering, we obtain the set S(1) = AB¯ + AC¯ which suggests the compos-
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ite pathway segment: Ψ 1:1,1−→ S(1).
Now Ψ 1:1,1−→ S(1) ⇔ ABC 1:1,1−→ AB¯ + AC¯
⇐ ABC
1:1,1
−→ AB¯ (choosing one)
⇔ ABC
1:1,1
−→ A (3.11)
& ABC
1:1,0
−→ B.
Thus, we get two new pathway segments : pathway 7 :ABC 1:1,1−→ A and pathway 8
:ABC
1:1,0
−→ B.
Conflict in the truth table of gene C: While trying to incorporate the simple pathway
segment 5, we get the conflict shown below for gene C.
Cnext:
x x
x x
xx
xx
0 0
0 0
00
00
A
C
B
D




	
Cpw5next:
x x
x x
xx
11
x x
x x
xx
11
A
C
B
D




	
Following the same procedure as we did for pathway 4, we see that Y1 = BC and the
new pathway segment is Y1
1:1,1
−→ C. The conflicting function Ψ is given by Ψ = ABC. As
before, supp(Ψ) ⊂ supp(Y1). Since Y1 > Ψ, we put a 1 in every minterm ∈ supp(Y1) =
supp(BC). The resulting K-map is shown below.
Cnext:
x x
x x
xx
11
0 0
0 0
00
11
A
C
B
D




	
Next we have to find a minimal set S(0) in the K-map which will suggest a new path-
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way segment for resolving the conflict. To do so, the 0s in the K-map of C can be clustered
below.
Cnext:
x x
x x
xx
11
0 0
0 0
00
11
A
C
B
D








	
From this clustering, we obtain the set S(0) = AB¯ + AC¯ which suggests the compos-
ite pathway segment: Ψ 1:1,1−→ S(0).
Now Ψ 1:1,1−→ S(0) ⇔ ABC 1:1,1−→ AB¯ + AC¯
⇐ ABC
1:1,1
−→ AB¯ (choosing one )
⇔ ABC
1:1,1
−→ A (3.12)
& ABC
1:1,0
−→ B.
Thus, we arrive at the same two pathway segments as before, pathway 7 :ABC 1:1,1−→ A and
pathway 8 :ABC 1:1,0−→ B.
Solution of pathways 7 and 8: There are no additional conflicts introduced while trying
to incorporate these two pathway segments. The implementation for pathway6 is shown
below.
Anext:
x x
x x
xx
xx
x x
x x
xx
11
A
C
B
D




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Pathway 7 :ABC 1:1,0−→ B has already been implemented in the K-map for gene B as shown
below and so no additional conflicts are created.
Bnext:
x x
x x
xx
00
1 1
1 1
11
00
A
C
B
D
Thus, the final set of K-maps, devoid of all conflicts, is shown below.
Anext:
x x
x x
xx
xx
x x
x x
xx
11
A
C
B
D Bnext:
x x
x x
xx
00
1 1
1 1
11
00
A
C
B
D Cnext:
x x
x x
xx
11
0 0
0 0
00
11
A
C
B
D Dnext:
x x
1 1
00
11
x x
1 1
00
11
A
C
B
D
E. Network design to satisfy additional constraints
The pathway information constitutes prior biological knowledge and in the previous sec-
tions we have shown how to generate a family of Boolean networks consistent with the
given pathway information. However, the cardinality of this family is still quite large and it
is reasonable to incorporate other available knowledge and experimental results to further
shrink the size of this family. One relevant piece of information that can aid in this is the
number, location and relative significance of the attractors. Since the procedure developed
earlier provides us with the final Karnaugh maps for each gene, one can easily check to
see if the attractor constraints can be satisfied. This is most readily demonstrated using our
earlier example.
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1. Imposition of attractor constraints
Consider the same example that we considered in section B and section D to construct a
family of BNs from pathways. Now, let us additionally assume that experimental data have
given us a steady state distribution. For a BN, for the steady state behaviour, one would ex-
pect zero probability mass in the transient states and non-zero mass only for the attractors.
However, due to the fact that the system is not an ideal BN (possibly a more general Prob-
abilistic Boolean Network which is equivalent to an ergodic Markov Chain), there could
be some non-zero mass in the transient states too. Also there can be some noise in the
data as well. Therefore, for inferring a BN from experimental data, a threshold should be
established for extracting the attractor states. Suppose that experimental data gives us the
steady state distribution shown in Fig 17 for our four gene network. Furthermore, suppose
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Fig. 17. Steady state distribution and threshold.
that for this example the threshold is chosen to be 0.08. This yields the attractor states:
0010, 0101, 1011 and 1101. Next we need to check whether these attractors are consistent
with the family of BNs that we determined in section D. For an attractor to be consistent
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with a family of BNs, the rules of regulatory interaction between the genes of each network
should guarantee that an attractor transitions only to itself. This can be easily verified from
the truth table for the update of each gene. We see that three of the attractors, namely 0010,
0101 and 1101 are consistent with the truth tables shown below.
Anext:
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However, the attractor 1011 is not consistent with these truth tables, thereby suggesting
that it may not be a valid attractor. To remove the state 1011 from the set of attractors
obtained from the data, we can increase the threshold to 0.11, say. Thus, the family of BNs
that we have constructed based on pathway information provides a useful way to eliminate
attractors whose steady state mass is near the threshold value. On the other hand, if we
get some attractor state whose steady state mass is very high (say 0.9) and it still contra-
dicts the truth tables obtained from the pathway knowledge, then we have every reason to
question the validity of the pathway information that has been provided to us. So, in that
case, the steady state distribution data can be used to assess the accuracy of our pathway
information.
2. Boolean network from predictors
Suppose that in the above example, one imposes the additional constraint that the maxi-
mum number of predictors allowed for each gene is 3. Such an upper limit on the number
of predictors per gene could be motivated from the biological consideration that the pro-
moter region for a gene only has enough room for at most only a few transcription factors
to bind. We currently do not have a systematic procedure for imposing such a predictor
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constraint. However, arbitrarily putting in some 1’s and 0’s for the x’s, it is possible to use
the four truth tables derived in section E.1 to arrive at a reasonable Boolean Network by
using a Karnaugh Map. For instance, by considering the truth tables (K-maps) as shown
below, taking the circled minterms and filling up all the x’s by 0, we obtain the the Boolean
rules (Eqn.(3.13)).
Anext:
x x
x 0
0x
xx
x x
1 1
xx
11
A
C
B
D
 
Bnext:
1 1
1 1
0x
00
1 1
1 1
11
00
A
C
B
D
 




Cnext:
x x
x 0
11
11
0 0
0 0
00
11
A
C
B
D








Dnext:
1 1
1 1
00
11
1 1
1 1
00
11
A
C
B
D








Anext = AB
Bnext = AB¯ + C¯
Cnext = (A¯+ B)C (3.13)
Dnext = B + C¯
This is a Boolean network with at most three predictors per gene and it satisfies the original
pathway constraints, after some minor timing modifications. As discussed earlier, such mi-
nor timing modifications are inconsequential since biological pathway information usually
does not come with strict timing. Next we can determine the attractor and attractor basins
for the generated network. For the network given in Equation (3.13), the state transition
diagram and the attractors are shown in Fig 18. From the state transition diagram in Fig
18, it is easy to verify that the state trajectories obey the original pathway constraints, of
course with the timing possibly altered. For instance, consider the state trajectory 1010→
0100→ 0101 marked in purple in Fig. 18. The red numbers in this trajectory show that the
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Fig. 18. State transition diagram for the Boolean network described by Equation (3.13).
following pathway relationships are realized: A = 1 implies B = 1 and C = 0 after one
time step. B = 1 implies D = 1 after one time step. Similarly, the blue numbers show the
realization of the pathway relationships: C = 1 implies D = 0 in one time step.
F. Modeling pathways involving the p53 gene
Some of the most widely studied pathways in molecular biology involve the tumor suppres-
sor gene p53. In fact, p53 is the “Master Guardian” gene[8] which plays a very important
role in cancer. Indeed, it has been observed that p53 is mutated in 30% − 50% of com-
monly occurring human cancers [8] and more importantly some parts of the p53 pathways
are altered in almost all types of human cancer. Thus, the dynamical behavior of p53 and
its tight regulation has become one of the most widely studied problems in cancer biology
[68, 69, 70, 71, 72, 73]. Unlike many other important regulated genes, p53 is constitu-
tively expressed in the cell. However, the p53 protein concentration is low under normal
conditions. This constitutive but low expression is maintained by the Mdm2 protein: p53
being a transcription factor expresses Mdm2 which in turn binds to p53 and promotes its
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ubiquitination and degradation [5]. Since the protein-protein interactions occur on a much
faster time scale than transcription and translation, the presence of active p53 is usually not
detected in a normal cell under normal conditions. The biological reason for the consti-
tutive expression of p53 is that it facilitates a fast response in the face of extreme stress:
it is much easier and faster to stop the degradation of p53 protein (by blocking the neg-
ative regulators) than turning on the un-expressed p53 gene. The primary role of p53 in
mammalian genomes is its function as a transcription factor for hundreds of downstream
genes. The expression of these downstream genes can modulate cell cycle progression, re-
pair damaged DNA, induce senescence and apoptosis. A detailed discussion of the cellular
processes mediated by p53 can be found in [8]. Although there are hundreds of genes that
are downstream of p53, our main goal here is to model the dynamics of p53 itself. So, we
focus on the pathways known to be important for p53’s regulation. From [3], we get some
major pathways involving p53 which are activated in the presence of double strand DNA
breaks. These pathways are shown in Fig. 19. In the following subsections we develop the
Boolean Network from the pathways of Fig. 19 using the method of this chapter. There-
after, we simulate the dynamic behavior of the resulting BN. Finally we validate our model
by matching our model’s time course behavior with the p53-related experimental results
reported in [74, 5].
1. Boolean network modeling of the p53 pathways
The pathway segments from the pathways in Fig.19 are: 1.dna dsb 1:1,1−→ ATM , 2.ATM 1:1,1−→
p53, 3.p53
1:1,1
−→ Wip1, 4.p53
1:1,1
−→ Mdm2, 5.ATM
1:1,0
−→ Mdm2, 6.Mdm2
1:1,0
−→ p53,
7.Wip1
1:1,1
−→Mdm2, 8.Wip1
1:1,0
−→ ATM .
Here the external signal is dna dsb, the DNA damage input. The state space is defined as
[ATM, p53,Wip1,Mdm2]. Using the methodology developed in earlier sections we get
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the following Boolean update functions for the 4 genes:
ATMnext = Wip1(ATM + dna dsb)
p53next = Mdm2(ATM +Wip1)
Wip1next = p53 (3.14)
Mdm2next = ATM(p53 +Wip1).
This Boolean network will have two different contexts based on the value of the external
signal dna dsb.
If dna dsb = 0, we get the state transition diagram of Fig. 20.
We can see the state transition diagram of the Boolean network has only one attractor
0000. Now our prior biological knowledge [8] indicates that in absence of any stress, all
four proteins are required to be inactive in the steady state. The presence of the singleton
attractor 0000 is consistent with the biological information. Next let us see what happens
if dna dsb = 1 i.e, the DNA damage input turns on. In this case, we arrive at the transition
diagram shown in Fig. 21 which corresponds to the other interesting context. Notice that
here there is a single cyclic attractor involving cyclic variation in the expression patterns of
all the four genes.
2. Model validation using the published literature
To further understand the functionality of the context sensitive Boolean network of Eqn.
3.14, we carried out the simulation described next. Suppose that initially the network state
is evolving in the absence of the DNA damage signal and that at a certain time (say, t =
25 time steps), the DNA damage signal dna dsb is activated. Let us further assume that
the DNA damage signal dna dsb returns to 0 at time = 75 time steps. The simulated time
course behavior of the expression patterns of the different genes is shown in Fig. 22.
From this simulation we can see that the proteins initially reach the steady state of
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Fig. 19. ATM-p53-Wip1-Mdm2 pathways (From [3]).
75
Fig. 20. State transition diagram for the Boolean Network of the p53 pathways under normal
conditions.
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Fig. 21. State transition diagram for the Boolean Network of the p53 pathways in the pres-
ence of DNA damage.
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Fig. 22. Oscillation of the proteins in the presence of the DNA damage signal.
deactivation if the cell doesn’t receive any stress causing DNA damage. However, once the
onset of DNA damage occurs, the oscillation starts. Furthermore, the oscillation continues
until the DNA damage is repaired (or the cell dies). The pattern of the oscillation is also
unique. ATM leads the oscillation followed by p53, Wip1 and Mdm2 in that order. This
dynamic behavior of the four proteins is consistent with published experimental results
from the p53 literature.
Indeed [74] discusses the experimentally observed oscillations between p53 andMdm2
in the presence of external stress. In that paper it is also reported that the Mdm2 protein
response lags behind the p53 response. [4] reports an interesting time series experiment
of p53 and Mdm2 oscillation and the results are shown in Fig. 23. Similarly [5] reports
the DNA damage induced oscillation patterns of ATM , p53, Wip1 and Mdm2 along with
some other proteins. Fig. 24 demonstrates that the p53 response lags behind the ATM
response; Fig. 25 demonstrates that the Mdm2 response lags behind the p53 response; and
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Fig. 23. Timelapse fluorescence images of one cell over 29 h after 5 Gy of gamma irradia-
tion. Nuclear p53-CFP and Mdm2-YFP are imaged in green and red, respectively.
Time is indicated in hours. Adapted by permission from Macmillan Publishers Ltd:
[Molecular Systems Biology] [4], copyright (2006)
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Validation..
Fig. 24. Immunoblots of ATM-P(S1981), Chk2-P(T68), and p53 kinetics in MCF7 cells
irradiated with 10Gy of gamma-irradiation. Reprinted from [5], Copyright (2008),
with permission from Elsevier.
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Fig. 25. Immunoblots of Chk2-P(T68), p53, and Mdm2 kinetics in MCF7 cells treated with
400 ng/ml NCS every hour. Blots are representative of triplicate experiments.
Reprinted from [5], Copyright (2008), with permission from Elsevier.
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Fig. 26. Immunoblots of p53 and Wip1 kinetics in MCF7 cells irradiated with 10 Gy of
gamma-irradiation. Reprinted from [5], Copyright (2008), with permission from
Elsevier.
Fig. 26 demonstrates that the Wip1 response lags behind the p53 response. Thus the net-
work that we have generated based on only p53 pathway information is able to qualitatively
reproduce experimentally observed p53 behavior from published literature. This is a very
positive development which suggests that the full potential of the approach presented here
remains to be explored.
G. Concluding remarks
In this chapter, we have presented a complete solution to the problem of determining a
family of Boolean networks that can generate trajectories consistent with given pathway
information. The solution makes use of the Karnaugh map realization of a Boolean func-
tion. In the case where the different pathways can be implemented without any conflicts in
the associated Karnaugh maps, the generation of the family of Boolean networks is straight-
forward. When a conflict does arise, a systematic procedure is presented to resolve it by
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slightly perturbing the original pathway information. The resolution of a particular conflict
may lead to the emergence of additional conflicts further downstream, and the resolution of
these conflicts would require repeated use of the same conflict resolution procedure. When
the resolution of the progressively downstream conflicts leads back to one of the original
conflicts further upstream, the problem is not solvable. In all other cases, the procedure
presented here converges to a family of BNs whose trajectories are consistent with the
given pathway information or minor variations thereof. As demonstrated here, further re-
duction in the cardinality of the family of networks can be achieved by imposing additional
constraints such as the number and relative significance of the attractors, upper bounds
on network connectivity, etc. The approach developed in this chapter has been applied to
the well studied p53 pathway and it has been shown that the resulting network exhibits
dynamic behavior consistent with experimental observations from the published literature.
We believe that the results presented here and their future extensions will significantly
impact all areas of biology where prior knowledge is present in the form of signalling path-
ways and where genetic regulatory networks are used to model multivariate gene relation-
ships. In particular, all of the currently available results in the genomic signal processing
area pertaining to inference and intervention in genetic regulatory networks will have to
be revisited to permit the incorporation of valuable pathway information. For cancer ge-
nomics, this would mean that in future, intervention design would be carried out with more
accurate and more easily inferred models thereby greatly enhancing the likelihood of these
methods succeeding in practice.
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CHAPTER IV
FAULT DETECTION AND INTERVENTION IN BNS*
In this chapter, our goal is to go a few steps further from where we left in CHAPTER
III. Here, we are not content with just producing a Boolean network model from given
pathway information. Instead our objective is to utilize such a model to (i) enumerate all
the possible fault scenarios; (ii) use the response of the model to a test input to determine
which fault or class of faults has occurred; and (iii) finally use this information to prescribe
an appropriate therapeutic action. To keep the discussion biologically focussed, we will
consider two biological examples, one for a combinatorial Boolean network and the other
for a sequential Boolean network. The chapter is organized as follows. In section A, cancer
is modeled as an ensemble of faulty Boolean Networks. In section B, drug therapies are
modeled as interventions to alter aberrant network behavior emanating from a fault. Section
C and D gives the first biological example (growth factor mediated signalling pathways)
showing the power of our methodology. Specifically, fault classification and intervention
results for our example are presented. Section E gives the second example (p53 mediated
DNA-damage pathways) showing the effectiveness of our approach for sequential Boolean
networks as well. Finally section F contains some concluding remarks.
A. Modeling cancer as faults in the signaling network
In molecular biology, the marginal behavior of the normal cell is described using signaling
pathways. Boolean networks represent a paradigm that can be used to incorporate this in-
formation to model the overall dynamic behavior of the cell, consistent with the pathway
*Part of this chapter is reprinted with permission from “Cancer therapy design based
on pathway logic” by R. Layek, A. Datta, M. Bittner, and E. R. Dougherty, 2011, Bioin-
formatics, vol. 27, no. 4, pp. 548555, Copyright [2011], Oxford University Press.
(http://bioinformatics.oxfordjournals.org/content/27/4/548.short)
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knowledge. However, the translational motivation behind this type of dynamical modeling
is to facilitate corrective intervention when the cell behaves abnormally. Cancer is actually
a disease of several faults in the network. A ‘fault’ is defined by any structural error of
the physical system, such that the dynamics become aberrant. For example, the accumula-
tion of point mutations in the genomic DNA may cause the signaling pathways to behave
erratically leading to proliferation. On the other hand, sometimes the fault may not be in
the genetic code of a particular protein, but rather it is in the protein synthesis factory ribo-
some, or in some control mechanism of alternative splicing. The fault could also be in the
chromosomal spindle resulting in unequal splitting of the chromosomal DNA between the
two daughter cells during cell division. Any of these different kinds of errors could cause
structural changes in the regulatory network, thereby changing its dynamics and steady-
state behavior. In this section, we try to model different types of biological errors within
the Boolean network (digital electronics) framework. In a Boolean Network, the faults can
be broadly divided into two types.
• Stuck-at Fault: A stuck-at fault means that a point in the network circuitry is stuck to
a particular value. As a result, the incoming information is no longer communicated
beyond the faulty point; instead, only the stuck-at value is passed on to the outgoing
port. Clearly stuck-at faults can commonly be of two types: ‘stuck-at-1’ faults and
‘stuck-at-0’ faults with obvious interpretations. We next present an example to show
that modeling via stuck-at faults makes biological sense.
In the Mitogen Activated Protein Kinase (MAPK) pathways, an important signaling
protein kinase is the Ras protein. Ras is phosphorylated by many upstream proteins
(by Growth factor mediated pathways). Once activated, Ras activates downstream
proteins which have transcriptional control on cyclin D1 and hence cell cycle pro-
gression. However, the inherent enzymatic GTPase activity of Ras hydrolyzes the
active Ras-GTP complex into the inactive Ras-GDP complex, so that Ras activity
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ceases after some time delay. However, if due to some mutations in the Ras gene, the
GTPase activity of the Ras protein is lost, the once activated Ras protein will be con-
stitutively active and will signal the downstream transcription causing proliferation
and cancer [8]. This constitutive activation of Ras can be modeled as a ‘stuck-at-1’
fault in the Ras node of the Boolean network model of the cell signal transduction.
Indeed, the “stuck-at” fault is a very common one in cancer biology. One of the ear-
liest findings of a very prevalent mutation in cancer was the identification of the Ras
oncogene family members, HRAS, KRAS and NRAS. These genes play a critical
role in the signaling that drives proliferation. KRAS genes constitutively activated
by mutations are found at the very high rate of 17-25% in human cancers [75].
• Bridging Fault: As the name suggests, a bridging fault refers to the disruption of old
interconnections and incorporation of new interconnections in the network. Bridging
faults also make biological sense. The molecular signal transduction relies on the
sequences and 3 dimensional conformations of the molecules involved. So, any vari-
ation in the sequence and 3 dimensional conformation of a molecule (mainly protein)
will alter its functionality. As a result, many pathways involving that molecule will
become inactive while the altered molecule may open up new ones. Without any loss
of generality, this kind of aberrant behavior could be modeled as a bridging fault in
the Boolean network.
Indeed, the “bridging” fault is also a common occurrence in human cancers. A wide
variety of tumor types carry chromosomal translocations, where parts of different
chromosomes have been joined together. The first such event to be associated with
a specific cancer is the Philadelphia chromosome, a translocation joining chromo-
somes 9 and 22 [76] and fusing the BCR and ABL genes. The event makes the
action of the Abl kinase constitutive in its stimulation of proliferation and inhibition
of DNA repair and, if this happens in early blood cell progenitors in the bone marrow,
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can cause chronic myelogenous leukemia. A variety of drugs that inhibit this kinase
activity can produce remission of the disease.
Stuck-at faults and bridging faults are illustrated in Fig. 27, where a fault free Boolean
network is shown in Fig. 27a while the corresponding faulty network is shown in Fig. 27b.
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Y
Fig. 27. Stuck-at faults and bridging faults in a digital circuit.
Based on the preceding discussion, it is clear that cancer can be broadly modeled as
multiple stuck-at and bridging faults in the Boolean networks corresponding to the normal
signaling pathways. In [77], extensive theoretical work on digital system testing and fault
modeling is presented which engineers have been successfully using for digital circuit test-
ing for quite some time now. One of the goals of this chapter is to use a similar approach
for the prediction of fault locations in cancerous networks and the design of intervention
policies to compensate for the effect of these faults. For the sake of simplicity, we will
focus only on single stuck-at faults. The more general case of cancer modeling involving
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multiple stuck-at and bridging faults will be taken up in future research.
1. Test inputs and fault detectability
Consider the BN of Fig. 27a which has 4 inputs and 2 outputs as shown. Now suppose that
the only possible fault in this network is the stuck-at-1 fault shown in Fig. 27b. Following
[77], for a combinatorial circuit (i.e, non-feedback BN) N , let Z(x) denote the output
vector for the input vector x. The presence of a fault f transforms N into Nf with output
function Zf(x) for the same input vector x. We say that a test vector t detects the fault f iff
Zf(t) 6= Z(t). Clearly, for the stuck-at-1 fault in Fig. 27b, the test input vector ABCD =
0000 can detect the fault because, Z(0000) = 01 while Zf (0000) = 11. However, the
test input vector 1111 cannot detect the fault since Z(1111) = Zf (1111) = 10. These
ideas about fault detectability will be applied to the biological examples in section C.3 and
section E.1.
B. Modeling drug intervention
In a cancerous network, identification of the fault locations is only a part of the task. The
major challenge lies in finding the best possible drug or drug combinations with which to
intervene. From a theoretical perspective, we can consider the non-cancerous and cancer-
ous (faulty) networks as two different Boolean networks. In general, it will be impossible
to make a cancerous network revert to the original non-cancerous one using any sort of
drug intervention, because the mutations leading to cancer are usually irreversible. Instead,
what the best drug combination could do is to nullify some of the deadly effects (like con-
stitutive cell division) of the cancerous faulty system and try to kill the cell by inducing
apoptosis.
The following modeling of drug intervention is inspired by the biological effect of the
drug on the pathways. A drug goes into the cell to bind a particular kinase to deactivate
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its phosphorylating capability. This means that the drug can cut the effect of that particular
kinase on molecules further downstream. Hence, the drug can be modeled as an inverted
input to an ‘AND’ gate at the target point of the Boolean network. This schematic modeling
of drug intervention is shown in Fig. 28.
Fig. 28. Drug intervention modeling.
In this chapter, our goal is not to derive the mathematical expression for the optimal
drug intervention policy, since most mathematically derived policies may be difficult, or
impossible, to biochemically implement. Instead, our objective is to model known and
well tested cancer drugs separately and then to find the best sub-optimal combination of
drugs for a particular cancerous network. The method is described in detail in section C.4,
where it is applied to a biological example.
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C. Biological example: growth factors and cellular signal transduction
In multicellular eucaryotic organisms, the cell numbers are very tightly controlled, and cells
divide to form more cells only when they receive signals from other cells directing them to
do so. The external signals that stimulate a cell to divide are usually called growth factors
or mitogens. Normally these are protein or steroid ligands. The external signal directing a
cell to divide is usually communicated to the cell division machinery inside the cell through
a transmembrane protein called a growth factor receptor. These transmembrane proteins
contain the amino acid tyrosine and activate the cell division machinery inside the cell by
phosphorylating some key proteins; hence, they are also sometimes referred to as receptor
tyrosine kinases. Each growth factor binds to its membrane bound receptor with great
specificity and when that happens, an intracellular signaling cascade occurs that can result
in enhanced cell proliferation, enhanced protein synthesis or inhibition of apoptosis. In
this chapter, we will focus on the signaling pathways associated with a number of growth
factors. One of the reasons for this choice is that these signaling pathways have not only
been widely studied in the context of cancer but also different cancer drugs, known to affect
different parts of the pathways, are currently available.
Before presenting a detailed schematic diagram of the components involved in these
pathways and their interactions, it is appropriate to first briefly review the eucaryotic cell-
cycle and point out how malfunctions in the associated control system can lead to cancer.
1. Cell cycle control, DNA mutation and cancer
In a multicellular organism, cell growth and proliferation are tightly controlled by the cell
cycle control system. The typical eucaryotic cell-cycle has four phases called G1(Gap 1),
S(Synthesis), G2(Gap 2) and M(Mitosis) as shown in Fig. 29. The resting phase G0 is a
phase where the cell has made a decision (in the G1 phase) to temporarily withdraw from
the cell cycle. The G0 and G1 phases are in equilibrium with each other so that a resting
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cell in the G0 phase can readily re-enter the cell cycle, if the external conditions require
additional cells to be produced. In the G1 phase, the cell processes all the extra-cellular
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Fig. 29. The eucaryotic Cell Cycle(G0: Quiscence, G1: Gap 1, R: Restriction point, S: Syn-
thesis, G2: Gap 2 and M: Mitosis) and the signal transduction pathways controlling
the cell cycle.
signals (through different pathways) and decides whether to go back to G0 or proceed to-
wards the S or DNA synthesis phase. The R checkpoint (see Fig. 29) is very critical in the
cell cycle regulation. Once the cell goes past the R checkpoint, the progression of the cell
cycle no longer depends on the mitogens (the growth factors or the inputs of the transduc-
tion pathways). Cyclin-CDK(Cyclin dependent kinase) complexes play major roles in the
regulation of the cell cycle dynamics. The growth factor activation of the receptor tyrosine
kinases results in rapid accumulation of Cyclin D1. Similarly in normal cells, removal of
growth factors results in rapid decline in the Cyclin D1 level. This Cyclin D(1 or 2) and
CDK4/6 complexes carry the cell past the R checkpoint. Beyond this checkpoint, although
there are mechanisms to check for correct DNA replication and proper apportioning of the
chromosomes between the two daughter cells, there are no more decisions made between
whether to remain in quiescence or to proceed to proliferation. Thus, after the R check-
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point, the cell cycle is more or less automated and independent of the extracellular inputs.
In normal cells, if there is no mitogen during the G0 ←→ G1 transition, the cell will not
enter the S phase. However, in cancerous cells, the proto-oncogenes can get mutated to be-
come oncogenes. The translated oncoproteins have 3 dimensional conformations which are
quite different from that of the corresponding normal protein and can behave differently.
For instance, if Ras proto-oncogene mutates to Ras oncogene, the encoded Ras oncopro-
tein can become constitutively active and start perpetually signaling to the downstream
proteins. In that case, even if there is no mitogenic signaling from the outside, the cell
will be stimulated to divide. Similarly mutation in pro-apoptotic genes can stop apoptosis
resulting in tumorigenesis. Since almost all the genes/proteins along the important prolif-
eration/apoptosis pathways are prone to mutation, the number of possibilities for mutation
leading to cancer is quite large.
D. Growth factor mediated pathways: combinatorial network
The particular set of signaling pathways that we will focus on in this first example are the
so called Growth Factor (GF) Pathways. Our goal is to model these signaling pathways as
an input-output Boolean circuit and to use the latter for (i) enumerating the different fault
(or malfunction) possibilities, (ii) carrying out fault classification and (iii) designing the
appropriate corrective action (or therapy). Such modeling must necessarily be preceded by
a biological understanding of the different components of this pathway and their interac-
tions. Fig. 30 is a schematic diagram showing the different components of this pathway and
their interactions, as currently understood by biologists, (for example the Kegg collection
of pathways (http://www.genome.jp/kegg/pathway.html) and the NIH BioCarta collection
of pathways (http://cgap.nci.nih.gov/Pathways/BioCartaPathways). The input nodes in
the diagram are the growth factors (shown in the rhombuses in Fig. 30). The external sig-
nals corresponding to the growth factors are transmitted through the kinase cascades and
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finally activate the appropriate transcription factors. The black and red lines in the diagram
indicate relationships which are known to be activating and inhibitory, respectively. Fig.
30 also shows six different cancer drugs (red boxes) and the points in the pathway where
they are believed to intervene.
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Fig. 30. A schematic diagram of the growth factor signaling pathways (the yellow color is
used for the reporter proteins which will be measured in future experiments).
These signal transduction pathways in Fig. 30 constitute a module in a larger tightly
controlled network of cell growth, cell division and metabolism.
Believing these pathways to be true, we can develop another level of abstraction by
modeling using Boolean Networks (BNs). For most of the pathways the modeling is trivial.
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Using the methodology of CHAPTER III, the modeling approach is quite intuitive and
logical and can be applied to the pathways in Fig. 30 to arrive at Fig. 31.
This module can be easily modeled using the Boolean circuit shown in Fig. 31, where
the seven outputs of interest, shown at the bottom of the figure, are transcription factors
(marked in green) and the activation status of some key proteins (not colored). As we
will see, such a Boolean circuit model can play an important role in understanding the
proliferation versus quiescence decision for a cell.
1. Input-output simulation of the BN
Since, there is no feedback path in the BN of Fig. 31, the current states are independent
of previous states. Also we are not concerned about the entire state vector, rather we are
primarily interested in the output response of the network. Hence, the complete input-
output mapping is essential for understanding the dynamics of this BN. This mapping is
shown in Table VI.
It is evident from the simulation that only the input of 00001 provides the ‘all-zero
output response’. This is again intuitive because 00001 means all the growth factors EGF,
HBEGF, IGF and NRG1 are inactive and the negative regulatory protein PTEN is high.
This input condition is crucial for investigating the fault scenario inside the network.
2. Modeling faults and therapeutic interventions using the Boolean network
Any mutation of any gene or post transcriptional modification of the corresponding protein
can constitutively turn ‘ON’ or ‘OFF’ that particular protein. This fits in precisely within
the stuck-at fault paradigm considered in section A. For the sake of simplicity, in our
growth factor pathways case study, we will consider only single faults of the stuck-at type.
In addition, we will only consider the stuck-at faults which can lead to cancer. For the
Boolean circuit shown in Fig. 31 the possible locations for the different stuck-at errors,
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Fig. 31. An input output Boolean network model of the signalling pathways of Fig. 30.
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Table VI. Input-output Mapping of the Boolean Network of Fig. 31.
Input Output Input Output
00000 0000111 10000 1111111
00001 0000000 10001 1111111
00010 1111111 10010 1111111
00011 1111111 10011 1111111
00100 1111111 10100 1111111
00101 1111111 10101 1111111
00110 1111111 10110 1111111
00111 1111111 10111 1111111
01000 1111111 11000 1111111
01001 1111111 11001 1111111
01010 1111111 11010 1111111
01011 1111111 11011 1111111
01100 1111111 11100 1111111
01101 1111111 11101 1111111
01110 1111111 11110 1111111
01111 1111111 11111 1111111
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which can induce proliferation and stop apoptosis, are shown in Fig. 32a. The numbers are
color coded to distinguish between the ‘stuck-at-1’ and ‘stuck-at-0’ faults. Specifically, the
black numerals refer to the stuck-at-1 faults while the red numerals refer to the stuck-at-0
faults.
As discussed in section B, a drug targets particular enzymes along the pathways and
cuts off the connectivity of that enzyme to the downstream proteins. This connection cleav-
age can be achieved via various mechanisms. For instance, the drug may have the capability
to bind a target protein and inhibit it from undergoing phosphorylation. For our case study,
we consider six potent cancer drugs. Our objective here is not to study their detailed mech-
anisms of action. Instead, we are interested in using the knowledge from biologists to mark
in their intervention locations and corresponding activities on the Boolean circuit of Fig.
31. This leads to the effects shown in Fig. 32b. Such pictorial representation of the drug
activity information is useful.
For instance, let us consider the drug ‘lapatinib’ which is known to work on EGFR,
ERBB2 or ERBB3 by inhibiting the signaling capabilities of these receptor tyrosine ki-
nases. From Fig. 32b, one can conclude that the drug ‘lapatinib’ will likely be responsive
for the treatment of cancers caused by mutations in the receptor tyrosine kinases although it
will probably be ineffective against cancers caused by mutations in the Ras protein, which
lies further downstream. Two central objectives of this chapter are: (i) to use the infor-
mation contained in Fig. 32a to group the numbered faults into different classes; and (ii)
to use the information in Fig. 32b to predict which set of drugs/drug combinations would
be most effective against a particular fault. These objectives are pursued in the next two
subsections.
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Fig. 32. Possible fault locations and drug intervention locations: (a) proliferative stuck-at
fault locations and (b) intervention locations for the available cancer drugs.
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3. Fault analysis and classification
From Fig. 32a, we see that there are 24 possible fault locations. Alternatively, we could
have arrived at the fault locations based on our biological understanding. As already indi-
cated, in this chapter we will be confining ourselves to the analysis of single faults only. So,
for our purposes, the fault can be any one of the 24 faults in the figure. Carrying forward the
discussion from section A, we use f 1i to denote the fault at the ith location. Then the sample
space for the single fault modeling can be defined as F 1 = {f 11 , f 12 , f 13 , · · · , f 124}. Here the
superscript 1 refers to the fact that we are considering only single faults. Now if f 1i ∈ F 1
occurs, an input vector t detects the fault iff the output vector Z in the faultless system
differs from the output vector Zf1 in the faulty system. Mathematically Z(t) 6= Zf1(t). If
we cannot find such an input t, we say the fault is undetectable. In the circuit shown in
Fig. 32a, the only input vector which can detect any f 1i ∈ F 1 for this particular network
is V = 00001 which is achieved with EGF = 0, HBEGF = 0, IGF = 0, NRG1 = 0
and PTEN = 1. This is due to the fact that for any other binary input V, all the outputs
are equal to 1, regardless of whether a stuck-at fault is present or not. This result is not at
all surprising. Indeed, when there is no growth factor outside the cellular membrane and
also the tumor suppressor protein PTEN is active, we expect to see all the proliferative
transcription factors and anti-apoptotic factors deactivated or turned ‘OFF’. However, if
there are faults (mutations) in the signal transduction pathways, we could see proliferation
even in the absence of active input signals (mitogens).
a. Single fault simulation
In this subsection, computer analysis for the single fault model of the circuit in Fig. 31 is
presented. The single fault model of the Boolean circuit is shown in Fig. 32a. The input
vector is V = [EGF,HBEGF, IGF,NRG1, PTEN ]. Each input can take binary values.
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For this simulation we take V = 00001. The output vector is Z = [FOS − JUN , SP1,
SRF − ELK1, SRF − ELK4, BCL2, BCL2L1, CCND1]. For the fault-free circuit
we get the output Z(00001) = 0000000. Now for the 24 different faults which may induce
cancer in the given circuit, the outputs are tabulated in Fig. 33a.
16,17,18
Fig. 33. Single fault simulation: (a) output simulation in presence of all proliferative single
stuck-at faults for input V = 00001 and (b) equivalent faults for input V = 00001.
b. Fault classification
From the outputs shown in Fig. 33a, we can classify the faults into different groups of
equivalent faults. Faults which generate the same output vectors for a particular test input
vector are called ‘equivalent faults’ with respect to that input test vector. The information
in Fig. 33a leads us to sets of equivalent faults for the test input vector V = 00001. The
equivalent fault groups along with their corresponding outputs are shown in Fig. 33b.
From Fig. 33b, it is clear that any fault in the locations 13, 14, 15 cannot be detected
from the output since the corresponding output is the same as that for the fault-free case.
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Hence, this class of faults is said to be ‘undetectable’. It is true that ‘undetectable faults’
cannot be compensated for based on observations of the output. Assuming that the outputs
are true indicators of the processes being monitored, there is no reason why we should be
concerned with faults that do not manifest themselves in the outputs. Hence, this is not a
major concern especially if we are only interested in the behavior of the outputs.
4. Simulation results for drug intervention
Since we have only the 6 available drugs, we define a drug vector of length 6 as follows.
If a particular drug is applied it is assigned the value 1, otherwise it is assigned the value
0. Consequently, the drug vector space has cardinality 26 = 64. The simulation is carried
out for all of the possible faults, taken one at a time, and for each of the 64 different
drug vectors, and the corresponding outputs are computed. The drug vector is defined by
[lapatinib, AG825, AG1024, U0126, LY 294002, T emsirolimus].
a. Continuous real mapping of the output vector
To avoid introducing any possible ambiguity about the origin of the proliferative signaling,
we take the same input vector (00001) that we have previously used for the fault analysis.
In the no fault case, with the drug vector 000000 we get the output 0000000 which is cer-
tainly non-proliferative. However, in the presence of faults, the outputs will be different.
The objective of this simulation is to determine the best possible drug sequence which can
nullify the effect of the fault, i.e, produce an output close to 0000000 or away from the
proliferative output 1111111. We note that although all the output vectors are represented
as binary numbers, assigning the usual binary weights to the digits here does not make
any biological sense. In other words, 1111111 here does not really mean 127 or 0000111
does not really mean 7. Consequently, we need to determine some transformation which
will map these 128 = 27 output vectors to a continuous real number scale in a biologically
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meaningful way. One way to do this is to proceed as follows.
If we examine the components of the output vector, we see that out of the 7 com-
ponents, 4 are transcription factors which express (turn ON) the important genes leading
to proliferation. The remaining 3 components capture the activation status of some key
proteins in the cytoplasm. So, these two groups of outputs have different biological signif-
icance and should be encoded separately. A possible mathematical transformation on the
output vectors is described next. The output vector is OUTPUT =[FOS − JUN , SP1,
SRF −ELK1, SRF − ELK4, BCL2, BCL2L1, CCND1].
Now suppose we take the number of active transcription factors as the first variable(F)
and the number of active remaining outputs as the second variable(S). The mathematical
transformation makes use of these two variables as described in Eqn. 4.2 below:
Output = [a, b, c, d, e, f, g]
F = a+ b+ c+ d
S = e+ f + g (4.1)
P = F × S
S = F + S
ψ(Output) = αP + (1− α)S,
where α ∈ (0, 1) is a design parameter. The above encoding scheme counts the number of
active transcription factors and the number of active key proteins, and combines these two
counts via a nonlinear many-to-one map, the idea being to quantify the degree of abnormal
behavior , e.g. proliferation in the absence of growth factors, etc. With α chosen as 0.5,
the function ψ’s values over the full sweep on the drug vectors and faults are shown in Fig.
34. Here the fault numbers and drug vectors are listed along the horizontal and vertical
directions respectively. The results are color coded for easier visualization, and the color
codes used are tabulated on the right side in Fig 34 .
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Fig. 34. Drug vector response in the presence of a single fault: (Left) output responses of
the circuit for all drug vectors in presence of all single stuck-at faults and (Right)
the map between the color codes and the output vectors.
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b. Interpretation of the result
From the output tables and the color codes we see that the color green corresponds to non-
proliferation while the color red corresponds to a high chance of proliferation even in the
absence of mitogenic signals. So, the best drug vector will be the one which can drive the
largest number of faulty circuits towards non-proliferative (green) outputs. For example,
the drug vector 000110 drives all of the faults 1 − 6 to green and most of the remaining
boxes along that row away from red. So, the drug combination of U0126 and LY294002
will likely be effective in producing a non-proliferative output. Another point to note is
that there can be faults (like fault 18 in Fig. 34) whose output cannot be altered using any
drug sequence. This is not at all surprising and is consistent with the pathway informa-
tion that we have. Indeed, the fault location 18 is at the ERK1/ERK2 protein and there
is no available drug in our list downstream of that protein. Consequently, no drug in this
particular case study would be able to block the effect of a mutatedERK1/ERK2 protein.
E. p53 mediated DNA damage pathways: sequential network
Since we have already discussed the modeling of p53 mediated DNA damage pathways in
CHAPTER III, we will not unnecessarily repeat it here. For further analysis, it sufficeth to
only recall the Boolean Network update equations.
ATMnext = Wip1(ATM + dna dsb)
p53next = Mdm2(ATM +Wip1)
Wip1next = p53 (4.2)
Mdm2next = ATM(p53 +Wip1).
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There are two contexts for this Boolean Network depending on the external signal dna dsb.
The state transition diagrams for both the contexts are given in Figs. 20 and 21. Clearly,
in the presence of DNA damage the activity of the 4 relevant proteins will oscillate to
normalize the behavior of the cell. However, if mutation strikes either of the 4 genes, the
question of interest becomes what the behavior of the transformed Boolean network will
be. The relevant fault analysis and possible intervention strategies are discussed below.
1. Fault analysis
We simulated the network for all the possible single stuck-at fault scenarios. The resulting
steady state behavior of the BN is shown in Table VII. The most interesting observation
is that the oscillations have ceased to exist. Analyzing the steady state (assuming the state
is observable), it is evident that the steady state singleton attractor corresponding to each
fault is unique. So, complete identification of all the single stuck-at faults for this network
is possible using just steady-state data. Recall that the state for this network is defined as
[ATM, p53, Wip1, Mdm2].
2. Intervention design
If the steady state of the BN of Eqn. 4.2 enters a singleton attractor with p53 = 0, the cell
loses the capability to repair DNA damage and this increases the risk of acquiring genetic
diseases including cancer. So, the objective of intervention design is to stop the replication
of mutated DNA. One way to do that would be to induce apoptosis especially if the DNA
cannot be repaired. Assuming that the therapeutic interventions utilize the kinase blocking
mechanism (section B), the simulation results of Table VIII show the possible corrective
actions.
105
Table VII. Steady State Attractors in the presence of Single Stuck-at Faults.
Fault DNA DSB = 0 DNA DSB = 1
ATM:s-a-0 0000 0000
ATM:s-a-1 1110 1110
p53:s-a-0 1000 1000
p53:s-a-1 0111 0111
Wip1:s-a-0 1100 1100
Wip1:s-a-1 0011 0011
Mdm2:s-a-0 0110 0110
Mdm2:s-a-1 1001 1001
Table VIII. Intervention Design for the Critical Faults in ATM-p53-Mdm2-Wip1 Boolean
Network.
Fault steady state(no control) control steady state(control)
ATM:s-a-0 0000 No solution -
p53:s-a-0 1000 No Solution -
Wip1:s-a-1 0011 Block Wip1/Mdm2 1100/0110
Mdm2:s-a-1 1001 Block Mdm2 0110
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F. Concluding remarks
In this chapter, we have presented a new approach for designing therapeutic intervention
policies based on available pathway information and the manner in which drugs target spe-
cific pathway connections. Relevant pathway information is first used to produce Boolean
networks whose state transitions are consistent with the given pathway information, or mi-
nor variations of it. The Boolean network is then used to (i) enumerate all the possible
fault scenarios; (ii) classify the faults into different classes based on their responses to a
particular test input; and (iii) prescribe an appropriate course of therapeutic action, tailored
to the fault or set of faults that has occurred.
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CHAPTER V
CONCLUSION
In this dissertation, it has been shown that modeling and controlling the cellular dynamical
system is a non-trivial task. The biologist’s idea of cellular interactions in the form of
signalling pathways can be modeled as Boolean Networks which can serve as the starting
point for further systematic research. For instance, if we know the underlying network
structure of a particular kind of gene-protein interaction experiment, we can predict the
dynamics associated with it. If the experimental result matches the prediction, the degree
of confidence in the model will be enhanced. Likewise, if the experimentation refutes
the prediction, we need to either increase the accuracy of the experiment or update the
knowledge base of the pathways. As we have already seen in the drug efficacy simulation
in CHAPTER IV, the simulation can enable us to predict the possibility of success of
a certain drug combination for a particular pathway. Experimental design based on the
predictive model can save us time and effort and the experiment can be focussed towards a
certain goal. Any mismatch between the drug’s observed response and the prediction result
will again lead to an update of our understanding of the drug as well as the model network.
The resulting iterative paradigm for systems biology is sketched in Fig. 35. Intuitively,
this update mechanism is the key for success in systems biology. Model based design of
experiments will eventually lead to more accurate estimation of the model.
The idea of personalized medicine for diseases like cancer can also be viewed in this
context. Genetic profiling of a new patient will decide the first level of diagnosis of the ge-
netic mutations. The systems biologist will then decide the relevant pathways in the tumor
from the marginal gene profiling data. Thereafter, the network can be constructed and in
vitro experiments can be performed on the tumor cells to get the right drug combination
from the drug database. This procedure which can be iterated upon has the potential to
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Fig. 35. Iterative update scheme of pathways and therapeutic target point knowledge in sys-
tems biology.
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treat a cancer patient in a much better way than any traditional approach. The schematic
diagram for this personalized approach to medicine is given in Fig. 36.
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Fig. 36. Personalized medicine using systems biology.
The list of future research topics is essentially unending. There are so many pathways
in so many cell types, that a complete solution of the problem is probably not possible.
The subject of systems biology will also evolve as more inventions and discoveries are
made. However, for the sake of completeness of the current dissertation we mention a few
immediate future research problems:
• Analysis of the multi-fault scenario in Boolean networks.
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• Modeling of bridging faults in Boolean networks.
• Developing models for higher level cellular events like cell cycle, apoptosis, differ-
entiation etc.
• Modeling of metabolic regulation in the cell.
• Validating the mathematical models in vitro and in vivo.
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